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ABSTRACT 
 
 
Francisella tularensis (FT) is a Gram-negative coccobacillus and causative agent 
of a life-threatening disease commonly referred to as tularemia.  Due to the highly 
infectious nature of the organism, its previous development as a biowarfare agent and its 
potential use in acts of bioterrorism, this bacterium is listed as a Category A select agent 
by the Centers for Disease Control and Prevention (CDC).  Efforts to understand the 
pathogenic mechanisms of FT within the host environment are vital for the development 
of safe and effective vaccines, as well as treatments, against tularemia.  Though 
considered an intracellular pathogen, FT research of late has shown an abundance of 
extracellular bacteria in the plasma fraction of host's blood during infection.  The goal of 
these studies was to identify and characterize the interactions of Francisella tularensis 
with components of the host fibrinolytic system. 
 
Because many bacterial pathogens utilize proteins found in the host plasma 
fraction as a means to augment dissemination as well as to defend themselves against 
components of the host immune system, I first sought to determine if FT was able to 
bind these on its surface in vitro using fresh frozen human plasma.  By using an ELISA 
assay I was able to detect significant levels of plasminogen and fibronectin binding to the 
bacterial cell surface.  Based on this observation, further studies were designed to 
dissect possible in vitro and in vivo functions of these FT-bound host proteins. 
 
Plasminogen (PLG) is a zymogen that upon activation is converted into the 
serine protease plasmin, which plays a key role in the proteolytic degradation of fibrin 
blood clots.  Many pathogenic organisms have taken advantage of both the broad-
specificity and abundance of this circulating host protein by binding it to their surface, 
which not only gives the pathogen an ability to degrade extracellular matrix components 
for dissemination but also aids in the defense against host immune responses.  The 
ability of FT to acquire surface bound PLG that can be activated may be an important 
virulence mechanism that results in an increase in initial infectivity, survival, and/or 
dissemination of this bacterium in vivo. 
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CHAPTER 1.  INTRODUCTION 
 
 
Francisella tularensis 
 
 Francisella tularensis (FT) is a Gram-negative intracellular coccobacilli and the 
causative agent of a life-threatening zoonotic disease known as tularemia.  Being one of 
the most infectious bacteria known to man (LD50 ~10 organisms in humans for type A 
strains), F. tularensis is listed as a Centers for Disease Control and Prevention Category 
A select agent because of its potential use as a bioweapon.  Named after Tulare County, 
California, where in 1911 a plague-like disease in ground squirrels was described by 
McCoy and Chapin (1), F. tularensis has been found throughout the Northern 
Hemisphere and infects a variety of vertebrate and invertebrate hosts (1-2). Francisella 
is the only member of the family Francisellaceae and is composed of the two species F. 
tularensis and F. philomiragia. Of the two Francisella species, F. tularensis is made of 
four subspecies: tularensis (type A), holarctica (type B), mediasiatica, and novicida.  
 
F. tularensis subsp. holarctica, from which the attenuated live vaccine strain (FT 
LVS) was derived, is less virulent in humans than type A FT subspecies.  This 
subspecies of FT is mostly found in Europe and Asia, but also found in North America. 
type B FT is biochemically differentiated from most other Francisella species by its lack 
of citrulline ureidase activity and an inability to produce acid from glycerol.  Based on 
biochemical phenotyping, pathogenicity, and geographic distribution, three biovars of F. 
tularensis subsp. holarctica have been suggested but not yet recognized by international 
taxonomic committees:  biovar I eryS (erythromycin sensitive), biovar I eryR 
(erythromycin sensitive), and japonica (3). 
 
The most severe cases of human tularemia are often attributed to F. tularensis 
subsp. tularensis which make up approximately two-thirds of reported cases and found 
almost exclusively in North American infections (4). Type A FT can be biochemically 
differentiated from other species of Francisella by its demonstration of citrulline ureidase 
activity and by its ability to produce acid from glycerol fermentation.  Recently, genomic 
analyses have further divided F. tularensis subsp. tularensis into two distinct subclades, 
with the A.I clade being found mostly in the central and eastern United States and the 
A.II clade mostly in the western United States (5).  Hotspots of tularemia, especially 
those in and around Arkansas, are geographically associated with areas containing the 
A.I clade of FT (5).  
 
 
Environmental Sources of Francisella 
 
Though commonly associated with infections in lagomorphs, F. tularensis has 
been shown to infect a broad range of hosts (over 200), including mammals, birds, 
amphibians, and invertebrates.  Because of this extended host diversity, there has been 
some difficulty in identifying a primary reservoir and clear routes of infection for FT in the 
environment. Sources of infection with F. tularensis in man and mammals are often 
associated with blood sucking insects such as the deer fly (Chrysops discalis) (6-7), 
mosquitoes (8-9) and ticks (Dermacentor and Ixodes) (6-7, 10) that feed on the blood of 
infected animals.  Francisella has often been associated with waterways and is known to 
persist for long periods of time in moist environments.  Additionally, Francisella has also 
been shown to infect protozoans such as Acanthamoeba castellanii (11) and has also 
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been shown to reside in cysts of this amoeba for up to 3 weeks post-infection (12). 
Recent work has also shown the ability of F. tularensis subsp novicida to form biofilms 
on chitin (13), a component of many arthropods and invertebrates found in aqueous 
habitats, making this a possible method of both survival under nutrient poor conditions 
and transmission to mammalian hosts.  Overall, these data suggest that the life cycle of 
Francisella in the environment is quite complex and that this pathogen is well-suited for 
survival in a variety of conditions, whether inside or outside its chosen host. 
  
 
Natural Infection and Symptoms of Tularemia 
 
Cases of human infection with F. tularensis have often been noted in hunters of 
wild game, landscape laborers, and laboratory personnel (6, 14). Following exposure to 
this bacterium, symptoms of tularemia may become apparent in the range of 3 to 14 
days, which may depend on the route of infection, number of bacteria, and immune 
status of the host.  A fever is a general symptom in all forms of tularemia that in some 
cases could reach as high as 104˚F.  Other symptoms of tularemic infection may include 
chills, aches, and progressive weakness.  Infected blood-sucking insects (6-10) and 
open-wound contact with infected animal tissue (6, 15-16) are common causes of 
ulceroglandular or glandular (without ulcerous lesions) forms of tularemia.  It is believed 
that when bacteria enter the host through the broken skin they are carried by the lymph 
ducts to draining lymph nodes, causing a visible and painful enlargement of this tissue, 
followed by the dissemination of FT to other areas of the body.  
 
Two less common, but potentially serious forms of tularemia are the 
oropharyngeal and oculoglandular manifestations of the disease.  Ingestion of FT-
contaminated materials or water is associated with oropharyngeal tularemia, typically 
displaying a pronounced cervical lymphadenopathy (17-19). Another less common, but 
significant, FT infection is known as oculoglandular tularemia, which may be caused by 
touching the eye with a contaminated hand (7, 20-21).  
 
The pneumonic form of tularemia has the highest mortality (30-60% of untreated 
cases) and often is the result of inhalation of infectious particulate matter and aerosols.  
This form of the tularemia has been reported as the result of landscape workers 
inadvertently aerosolizing infected carcasses with lawn mowing equipment (18, 22-23). 
Farmers that have been involved with work such as hay-making have also been infected 
with pneumonic tularemia (24-25).  
 
 
Francisella as a Potential Bioweapon 
  
Due to the high virulence and low inoculum needed (approximately 10 
organisms) to cause a potentially fatal infection (26-27), this organism was studied in 
bioweapon programs in Japan, the United States, and the former Soviet Union as an 
offensive weapon (28). Being that FT is easily isolated from the environment and can be 
grown to large quantities without sophisticated equipment, it is of considerable concern 
that this organism could be used by various terrorist groups worldwide to infect human 
populations on a large scale.  It has been estimated that 50kg of FT dispersed over a 
city of 5 million people would result in the infection of 250,000 individuals and 
approximately 19,000 deaths, with prolonged illness and relapses of infection lasting 
several weeks (29). The financial impact of such an intentional release of FT was 
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estimated by the Centers for Disease Control (CDC) to cost $5.4 billion per 100,000 
people infected (30) and would most likely overwhelm public health services.  The 
financial and life-threatening potential of FT has led this organism to be designated a 
Category A select agent by the CDC, a group which also includes other dangerous 
organisms such as those causing anthrax and smallpox. 
 
 
Vaccination against Tularemia 
 
It is believed that survival of tularemia results in life-long immunity to reinfection 
with this disease in humans, suggesting that a protective vaccine is possible. Attempts to 
develop a safe and effective vaccine against tularemia have been met with various 
degrees of success in the past.  Some of the first vaccination methods attempted were 
killed bacterial vaccines tested by Foshay during the 1930’s and 1940’s which consisted 
of formalized, heat killed, and oxidized preparations of virulent FT strains, all of which 
offered very limited protection against human tularemia although eliciting significant anti-
FT serum antibody titers (31). Protection against infection with F. tularensis is currently 
limited to scarification with an attenuated live vaccine strain (FT LVS) of F. tularensis 
subsp holarctica, but is currently not licensed and does not illicit complete immunity 
against infection with type A strains of FT (26-27, 32). An attenuated Ft Schu S4 strain 
was reported by Twine et al to protect mice against wild-type homologous challenge 
after sublethal infection, though currently untested in humans (33). Murine models of 
infection have shown that anti-FT antibodies alone are able to protect against infection 
with type B strains of Francisella (34), but in studies using the more virulent type A 
strains interferon-gamma as well as CD4+ and CD8+ T-cells are needed to survive a 
lethal bacterial challenge (35-36). Immunization of mice with LPS extracted from FT 
bacteria offers protection against lethal challenge infections with FT LVS, but fails to 
protect against challenge with the highly virulent FT Schu S4 strain (36-37). 
Furthermore, infection of mice using a mutant strain of FT LVS with a transposon-
inactivated wbtA gene results in an LPS O-antigen-deficient phenotype and further 
attenuation that offers protection in wt FT LVS challenge experiments (38-39) and 
suggests a dispensable role for anti-LPS antibodies in adaptive immune protection 
against lethal FT infection.  Work by Huntley et al have shown that the immunization of 
mice with isolated native outer-membranes from FT LVS were reported to increase 
survival as well as decrease bacterial dissemination to the spleen and liver after an 
intranasal challenge with type A FT Schu S4 (40). All together, these studies seem to 
suggest that both humoral and cell-mediated immunity directed towards components of 
the bacterial envelope may provide our best hope in developing a safe and effective 
vaccine against lethal FT infection.    
 
 
Survival of Francisella tularensis in the Host Environment 
 
  In the extracellular environment of the host, FT is resistant to complement-
mediated lysis (41). Of particular interest is a requirement of host complement C3 
deposition on the bacterial cell surface for opsonophagocytosis of FT by activating CR3 
and CR4-mediated phagocytosis in macrophages and dendritic cells (42-43). Upon entry 
into a susceptible vertebrate host, F. tularensis is readily phagocytized by resident 
macrophages and dendritic cells via spacious, asymmetrical pseudopod loops (43).  By 
a mechanism that is currently unknown, Francisella escapes from the phagosome 
beginning approximately one hour after being taken up by the phagocyte, prior to 
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lysosomal fusion and complete acidification of the vesicle and enters the cytoplasm (44). 
It then multiplies in the host cell cytoplasm (45-46) before an induction of ASC/caspase1 
and apoptosis with subsequent release of bacteria to initiate another round of infection 
(47-49). 
 
Genetic screening methodologies have identified many virulence genes 
associated with the ability of Francisella to infect host cells in vivo and in vitro, as 
reviewed by Meiborn and Charbit (50).  Following the completed sequencing of several 
Francisella genomes, a group of highly conserved genes were identified in all FT 
genomes to date and are known as the Francisella pathogenicity island (FPI) (51).  The 
FPI is approximately 30 kb in length and has been found in duplicate copies (51) within 
all known Francisella species except for F. novicida and F. philomiragia which have only 
a single copy (52).  Within this operon, six genes (pdpB, pdpC, iglD, iglC, iglB, and iglA) 
have been identified as virulence factors that are necessary for host cell infection (53-
58), though their functions are currently unresolved.  Mutational studies of other genes 
outside of the FPI, such as those thought to be involved in capsule production (capA, 
capB, and capC), pili (pilT, pilA, and pilF), LPS O-antigen synthesis, and various other 
uncharacterized membrane/envelope proteins have also been shown to play important 
roles in the ability of FT to survive in the intracellular and extracellular host environment 
(55-56, 58-59).    
 
Recent studies have shown that significant numbers of these released FT 
bacteria are found in the acellular plasma fraction of mice infected intradermally or 
intranasally with either FT live vaccine strain (LVS) (type B) or F.tularensis Schu S4 
(type A) (60), and intranasally with F. novicida (61). These findings suggest that, in 
addition to utilizing the intracellular cytoplasmic niche for replication and protection from 
humoral immunity, FT may also have a significant extracellular phase.  When taking into 
account both the high concentration and sheer multitude of proteins found in host 
plasma, there lies an opportunity for those freely circulating bacteria to interact with host 
molecules in ways to aid its survival and/or invasiveness within the infected host.  This 
poorly studied phase of FT infection deserves attention and may unveil potentially 
valuable molecular targets for the treatment and/or prevention of tularemia.   
 
 One very interesting example of how Francisella interacts with a host 
plasma/serum component can be found within work with factor H. Several studies have 
shown that deposition of host complement component C3 on the surface of FT is 
required for opsonophagocytosis by activating complement receptor (CR3 and CR4)-
mediated phagocytosis by macrophages and dendritic cells (42-43, 62). It is also known 
that FT is relatively resistant to complement-mediated lysis (41). A recent report 
suggested that resistance of FT to membrane attack complex-mediated lysis may be 
due (at least in part) to its ability to bind to factor H, a glycoprotein found in host plasma 
with complement regulatory activity (63). The normal function of factor H on the surface 
of host cells is to bind and inactivate C3 convertase (C3bBb) and ultimately prevent 
formation of the cytolytic membrane attack complex (MAC).  By binding soluble factor H 
from host blood, FT is able to prevent MAC formation on the bacterial envelope, yet at 
the same time, acquire a necessary protein (iC3b) for gaining entry into phagocytic cells 
via complement receptor-mediated phagocytosis (63).  It is possible that besides this 
ability of Francisella to bind to factor H, there lies the potential for other host plasma 
components to also play a significant role in its pathogenesis. 
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Interactions of Bacterial Pathogens with Host Plasminogen/Plasmin  
 
It has long been established that a broad spectrum of both Gram-positive and 
Gram-negative bacterial pathogens gain a survival advantage by interacting with plasma 
proteins, and in particular, those components of the host coagulation/fibrinolytic system 
in humans (64-67).  For instance, the ability to acquire surface-associated plasmin has 
been documented as an important virulence mechanism in Group A streptococci (68), 
Borrelia burgdorferi (69), and Yersinia pestis (70) by aiding in the organism’s ability to 
penetrate the extracellular matrix and to disseminate to distal sites in the host.   Borrelia 
burgdorferi has even been shown to utilize plasmin derived from the blood meal of ticks 
to aid in its passage from the gut to the salivary glands of its arthropod host, thus 
allowing the bacteria to be passed to a subsequent mammalian host (69). Plasminogen 
(PLG) is a 92-kDa glycoprotein zymogen that is involved in fibrinolysis. This precursor 
protein is converted to an active serine protease (plasmin) via cleavage of the peptide 
bond between residues R560 and V561 in vivo via urokinase-type (uPA) and/or tissue-type 
(tPA) PLG activators. Plasmin has an important role in blood clot resolution because of 
its role in the degradation of fibrin polymers. Because plasmin has other substrates that 
include pro-collagenases, pro-metalloproteinases, and extracellular matrix proteins, such 
as fibronectin, laminin, and vitronectin, the ability of a bacterium to acquire surface 
associated plasmin can result in an enhanced ability of the pathogen to penetrate the 
extracellular matrix and disseminate to distal sites in the host (64, 66, 68). 
 
 
Summary and Purpose 
 
 Francisella tularensis is a highly contagious bacterial pathogen with the potential 
to cause widespread illness and subsequently strain emergency response services in 
the event of a deliberate dispersal of the organism on human populations.  Despite the 
best efforts of Francisella researchers that have been attempting to unravel the 
mechanisms behind this stealthy and effective pathogen for nearly a century, our work is 
far from complete.  Though much work has been published on the intracellular aspect of 
its infectious cycle within the host, little has been shown on its extracellular phase which 
may provide valuable insight into Francisella pathogenesis.  The overall goals of the 
studies described in this work sought to focus on the following: 1) To characterize the 
possible interactions of Francisella with human plasma proteins that have been shown to 
be exploited by other bacterial pathogens, in particular, plasminogen, 2) To identify 
receptors for any plasma proteins on the bacterial outer envelope by proteomic 
methodologies, and 3) To characterize any possible functions for these plasma proteins 
that may aid in the pathogenesis of Francisella.  It is our hope that the studies described 
herein will contribute to the understanding of Francisella pathogenicity and to aid in 
efforts to develop treatments and vaccines against lethal tularemia.  
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CHAPTER 2.  MATERIALS AND METHODS 
 
 
Bacterial Strains and Culture 
 
   F. tularensis Live Vaccine Strain (FTLVS) was a kind gift of Dr. Karen Elkins 
(FDA, Bethesda, MD).  FT LVS-pLux was obtained from James Bina (UTHSC, Memphis, 
TN) and contains a constitutively-expressed lux operon from Photorhabdus luminescens 
with a FT promoter (pXB178). FT Schu S4 was obtained from the CDC.  All bacterial 
cultures were grown overnight frozen stocks in either Brain-Heart Infusion broth (37g/L, 
pH 6.8) or modified Mueller-Hinton (MMH) broth supplemented with 2.5% ferric 
pyrophosphate, 10% glucose, and 10% cysteine at 37˚C with shaking to mid-log phase 
(OD600 = ~0.7) before use. Bacterial stocks were made by pelleting an overnight culture 
and resuspending in MMH or BHI broth only.  Stocks were stored at -80˚C until use. 
 
 
Reagents 
 
  Human fresh frozen plasma (FFP) was purchased from Lifeblood Mid-South 
Regional Blood Center (Memphis, TN).  Human Glu-PLG, human single-chain tissue 
PLG activator (tPA), and the plasmin colorimetric substrate (H-D-Val-Leu-Lys-pNA) were 
purchased from Molecular Innovations (Novi, MI).  Bovine serum albumin (fraction V) 
was purchased from Thermo-Fisher Scientific (Pittsburgh, PA).  Polyclonal sheep anti-
human PLG and anti-human fibronectin antibodies were purchased from AbD Serotec 
(Raleigh, NC).  Monoclonal anti-goat/sheep IgG-horseradish peroxidase conjugated 
secondary antibody (clone GT-34) and ε-aminocaproic acid (A7824) were purchased 
from Sigma-Aldrich (St. Louis, MO).  Ninety-six well MAXISORP ELISA plates were 
purchased from Nunc (Rochester, NY). 
 
 
Plasminogen Binding ELISA Assays 
 
FTLVS was cultured overnight to mid-log phase in brain-heart infusion broth (pH 
6.8), pelleted at 6,400 x g for 30 minutes, washed twice with phosphate-buffered saline 
(PBS), and resuspended in PBS with 0.1% Na azide to an OD600 = 0.1.  The resulting 
bacterial suspension was added to microtiter plates (100 µl/well) before being incubated 
overnight at 4˚C to facilitate binding.  The wells were then washed twice with 200 µL of 
Tris-buffered saline (pH 7.45) containing 0.05% Tween-20 (TBST) to remove unbound 
bacteria and then pre-blocked with 200 µl of TBST containing 1% bovine serum albumin 
(1% BSA-TBST) for 1 hour at RT˚ to prevent non-specific protein binding.  After removal 
of the blocking solution, 90% citrated human plasma or 3 µg/mL human Glu-PLG in 1% 
BSA-TBST was added to each well (100 µl), with or without the indicated concentrations 
of εACA, and incubated for 1-2 hours at 37˚C with gentle rocking. Wells were washed 
three times with TBST and then sheep anti-human PLG-specific antibody (1:2000 
dilution in 1% BSA-TBST) was added (100 µl/well) and allowed to incubate for 1 hour at 
37˚C.  Unbound primary antibodies were removed by washing three times with TBST, 
followed by the addition of HRP-conjugated anti-sheep/goat IgG mAb (GT-34, 1:5000 
dilution in 1% BSA-TBST; 100 µl/well) and incubation for 1 hour at 37˚C.  Unbound 
secondary antibodies were removed by washing 4 times with TBST, and OptEIA TMB 
colorimetric substrate solution (Becton-Dickenson, Franklin Lakes, NJ) was added to 
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each well (100 µl/well) and incubated at 37˚C for 20 min. to allow color development. 
Absorbance at 450nm was determined using a SpectraMAX 340 plate reader (Molecular 
Devices, Sunnyvale, CA). 
 
 
Indirect Immunofluorescence Assays 
 
FTLVS was cultured and washed as previously described.  After diluting the 
washed bacteria to OD600 = 0.1, 1 mL aliquots were incubated with a total of 40 µgs of 
PLG or PBS (negative control) for 30 minutes at 37˚C with gentle rotation.  Bacteria were 
then washed three times with PBS by centrifugation, resuspended in 100 µl of PBS, 
followed by spotting 20 µl of each sample onto glass coverslips.  The samples were then 
air-dried overnight at 37˚C.  After methanol fixation, the coverslips were blocked with 1% 
BSA-PBS at room temperature before adding sheep anti-human PLG (1:100 diluted in 
1% BSA-PBS) for 30 minutes at room temperature.  The coverslips were gently washed 
with PBS before adding donkey anti-sheep/goat IgG:Dylight-488 (1:100 diluted in 1% 
BSA-PBS), followed by incubation for 30 minutes at room temperature.  After washing 
again with PBS, coverslips were mounted onto glass slides using 100% glycerol 
containing 0.1M n-propyl gallate and images were collected on a Zeiss LSM 510 
confocal microscope (Thornwood, NY) with an Axiovert 100M base with a 100X Plan 
Apochromat 1.4 NA oil DIC objective using the argon laser for 488 nm excitation and 
505-530nm bandpass emission filter for imaging Dylight488 fluorescence and the HeNe1 
543nm laser for illumination of the DIC images.  Both images were collected using 
identical detector gain and amplifier offset settings, and the images shown are 1.0 mm 
optical slices.  Digital images were visualized using Zeiss AxioVision LE software 
(Thornwood, NY). 
 
 
Chromogenic Plasmin Activation Assay  
 
FTLVS was cultured overnight to mid-log phase, washed twice with Tris-buffered 
saline (TBS) and then resuspended in TBS to an OD600 of 0.7. Aliquots of the bacterial 
suspension (50 µl) was added to 50 µl of TBS alone or TBS containing Glu-PLG (192 
μg/mL) and incubated for 1 hour at 37˚C. The cells were washed 3x with TBST 
containing 0.1% BSA, and pellets were resuspended in 200 µL of TBS and then split into 
two 100 µl aliquots. 50 µl of 50 mM Tris-HCl (pH 7.45) with or without 333 μM of the 
chromogenic plasmin substrate (H-D-Val-Leu-Lys-pNA) and 50 µl containing 1.2 µg of 
tPA or TBS alone was added to each sample and incubated at 37˚C for 3 h.  Bacteria in 
each tube was pelleted via centrifugation and 150 µl of each supernatant was pipetted 
into a 96-well plate (in triplicate) and absorbance at 405 nm was determined as a 
measure of PLG activity. 
  
 
Membrane Protein Fractionation 
 
Outer membrane enriched fractions were isolated by a procedure adapted from 
de Bruin, et al (71).  FTLVS were grown in BHI broth (500 mL) to mid-log phase and 
then were pelleted via centrifugation at 6,400 x g for 30 minutes.  Cells were 
resuspended in cold PBS and then lysed by sonication.  Unlysed bacterial cells were 
separated from the whole-cell lysate by centrifugation at 10,000 x g for 20 minutes at 
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4˚C.  The insoluble membrane fraction was then isolated by ultracentrifugation for 1 hour 
at 100,000 x g at 4˚C.  After removal of the soluble protein fraction, the pelleted total 
membrane fraction was resuspended in 1% Sarkosyl with vortexing and subjected to a 
second round of ultracentrifugation for 1 hour at 100,000 x g at 4˚C.  The Sarkosyl-
insoluble pellet was resuspended in 50mM Tris pH 8. The protein concentration of both 
the Sarkosyl-soluble and Sarkosyl-insoluble fractions was determined using the DC 
protein assay (Bio-Rad, Hercules, CA) according to manufacturer directions. Samples 
were stored at -20˚C until use. 
 
  
Far-Western Blotting Analysis 
 
Approximately 100 µg of each protein fraction was precipitated using ice-cold 
acetone, pelleted via centrifugation at 18,900 x g at 4˚C for 15 minutes, and air-dried at 
RT˚.  The samples were then solublized by boiling in 1X SDS-PAGE sample buffer 
containing 2-mercaptoethanol. Duplicate 20 µl aliquots of each sample was subjected to 
15% SDS-PAGE to separate the proteins based on their size. One set of the samples 
was then electrophoretically transferred to a PVDF membrane (Immobilon-Psq, 
Millipore). The PVDF membrane was pre-blocked with 1% BSA-TBST for 1 hour at RT˚ 
to minimize non-specific protein binding, and was then incubated in a solution of Glu-
PLG (3 µg/mL in 1% BSA-TBST) for one hour with rocking at 37 ˚C. Unbound PLG was 
removed by washing three times with TBST. Sheep anti-human PLG-specific antibody 
(diluted 1:2000 in 1% BSA-TBST) was added (100 µl/well) and allowed to incubate for 1 
hour at RT˚ with rocking.  The PVDF membrane was washed three times with TBST to 
remove unbound primary antibody. The membrane was then incubated in a solution of  
horseradish peroxidase-labeled anti-sheep/goat IgG monoclonal antibody (GT-34, 
diluted 1:5000 in 1% BSA-TBST) with rocking for 1 hr at RT˚.  The PVDF membranes 
were washed 3 times with TBST to remove unbound secondary antibody. The blot was 
developed using Pierce PicoWest chemiluminescence reagents and imaged using a Bio-
Rad ChemiDoc XRS system (Bio-Rad, Hercules, CA). 
 
 
Proteomic Identification of Plasminogen-binding FT Proteins 
 
Protein bands were excised from Coomassie-stained SDS-PAGE gels, cut into 
small pieces, incubated in 50% acetonitrile/100 mM ammonium bicarbonate until 
colorless, and dried via vacuum centrifugation. The protein was digested by adding 20 µl 
of a 20 ng/µl trypsin solution and incubating overnight at 37˚C. Peptides were extracted 
from the gel slices via sonication in 50 µl 60% acetonitrile/5%TFA, dried via vacuum 
centrifugation, and reconstituted in 15 µl 0.1% TFA. Tryptic peptides were 
desalted/enriched using a C18 ZipTip column (Millipore, Billerica, MA) according to 
manufacturer’s instructions and the eluant was spotted on a MALDI plate and dried. 
Samples were analyzed using a MALDI-LTQ mass spectrometer (Thermo Finnigan, San 
Jose, CA). A full MS scan in high-mass range (m/z 600-4000, 5 microscans) was 
performed. The 50 most intense peaks in the full MS spectrum were selected, and 
MSMS scans were performed for those ions in high-mass range (m/z 50-4000, 5 
microscans), the normalized collision energy for MSMS was 35.  Xcalibur software 
(Thermo Fisher Scientific, Waltham, MA) was used process the mass spectrometric 
data, and the NCBInr database and the Bioworks 3.2 search engine software (Thermo 
Finnigan, San Jose, CA) were used for database searching.  
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In Vivo Imaging of Mice Infected with Luciferase-expressing FT LVS 
 
Female Balb/c mice (5/group) were shaved and treated with a depilatory cream 
to carefully remove hair from the ventral area of the neck and torso to decrease light 
obstruction during image collection.  Mice were lightly anaesthetized using Isoflurane 
before being intranasally infected with 1x106 CFU FT LVS-pLux (25 μl/nare) or given 
sterile PBS alone.  Six hours before infection, and every six hours for the duration of the 
experiment, mice were injected intraperitoneally with 200 μL of εACA (150 mg/mL) or 
sterile PBS alone (72).  Mice were granted access to chow and water ab libitum and also 
monitored daily for signs of disease.  Each mouse was weighed and imaged daily using 
a Xenogen IVIS system (Caliper Life Sciences, Hopkinton, MA) to note disease severity 
and progress, with mice losing greater than twenty percent of their starting body weight 
or having impaired mobility being humanely euthanized. 
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CHAPTER 3.  PLASMINOGEN/FRANCISELLA BINDING STUDIES AND THE 
IDENTIFICATION OF PUTATIVE BACTERIAL MEMBRANE-ASSOCIATED PROTEIN 
RECEPTORS 
 
 
Introduction 
 
The causative agent of tularemia, Francisella tularensis, is well-known among 
bacteriologists and physicians because of its highly infectious nature and potential to 
cause lethal infection in humans and other animals. Efforts to develop a safe and 
effective vaccine against tularemia have been unsuccessful to date and the only 
prophylaxis is by scarification with live vaccine strain of FT (FT LVS), though it is 
currently unlicensed and only available to military personnel and laboratory workers.  
Additionally, FT LVS was derived as an attenuated mutant of F. tularensis ssp. 
holarctica, a type B stain which is less virulent to humans than the type A F. tularensis 
ssp. tularensis (e.g. Schu S4) and has an unclear mechanism of attenuation. For these 
reasons, researchers in the field of FT vaccine research have been searching for 
alternative immunization strategies, such as using defined FT Schu S4 strains (33, 73-
74) and subunit vaccine preparations (36-37, 40). 
 
Francisella is not only one of the most infectious bacterial pathogens known to 
humans, but it also seems especially well prepared to survive in a wide array of other 
host environments as evidenced by its ability to infect over 200 species of vertebrates 
and invertebrates. Upon entering a mammalian host through breaks in the skin or by 
inhalation of infectious materials, FT bacteria are typically taken up by host phagocytic 
cells such as macrophages and dendritic cells.  These bacteria are then believed to be 
carried by lymphatic ducts to the local draining lymph nodes.  Later during the infection, 
FT spreads systemically and can be found in the liver, spleen, lungs, and freely 
circulating in the blood within or outside of phagocytic cells (60-61). Questions still 
remain as to how FT is able to spread so quickly (within days) to most areas of the host 
body and to the role that such high numbers of extracellular bacteria may play during its 
pathogenic cycle. 
 
One common mechanism used by pathogenic organisms to disseminate within 
the host is to utilize components of the host fibrinolytic system.  By taking advantage of 
both the broad specificity and the availability of relatively large quantities of the serine 
protease plasminogen (plasmin), many pathogens are able utilize the proteolytic activity 
of this host enzyme to promote penetration through the extracellular matrix as a means 
of dissemination as well as evasion of host innate immune responses (64-67). Bacterial 
pathogens have been shown to use a wide variety of both membrane and cytosolic 
proteins as plasminogen receptors, which suggests that the ability to bind plasminogen 
has proven itself beneficial as a means to allow safe passage within host environments. 
 
This chapter illustrates work describing the interaction of plasminogen with the 
outer surface of FT LVS and FT Schu S4. I have clearly demonstrated that plasminogen 
binds to the outer envelope of FT.  My work has also shown that plasminogen that has 
been pre-bound to the outer envelope of FT can be cleaved to its enzymatically active 
form (plasmin) by treatment with a plasminogen activator, as evidenced by its ability to 
cleave both a chromogenic plasmin substrate and an extracellular matrix component 
(fibronectin). Furthermore, I used a ligand blotting technique coupled with proteomic 
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methodologies to identify five putative plasminogen receptors from FT outer envelope 
preparations. 
 
 
Binding of PLG from Fresh Human Plasma to the Surface of FT LVS 
 
  Until very recently, there were no published works describing the potential for FT 
to bind plasma proteins belonging to the host fibrinolytic system.  Our first goal was to 
determine whether fibrinolytic plasma components could be recruited to the surface of 
FT. I used a simple enzyme-linked immunosorbant assay (ELISA)-based approach in 
which FT (grown to mid-log phase in modified Mueller-Hinton broth) was bound to 
microtiter plates and then incubated in the presence of fresh frozen plasma (FFP). I 
chose to use human fresh frozen plasma (FFP) as a source of ligands because it 
provides similar types and quantities of proteins that extracellular FT might encounter 
while circulating in the plasma fraction of whole blood. Binding of specific fibrinolytic 
plasma components was then detected using plasminogen-, fibrinogen-, and fibronectin-
specific secondary antibody preparations. As a positive control I also measured binding 
of factor H, a plasma component that has been shown to bind to the surface of FT (63). 
In addition, BSA-coated well were used to establish levels of non-specific binding of 
plasma components. The results of this assay revealed that both plasminogen and 
fibronectin bind to FT, and it confirmed that factor H binds to FT (data not shown). 
However, I found no clear evidence that fibrinogen binds to the surface of FT.  Though 
the binding of fibronectin to FT cannot be ruled out as a potential virulence factor at this 
time, I chose to focus my studies on the ability of FT to bind PLG because of its potential 
to enhance virulence and dissemination/invasiveness within the host. 
 
In light of published findings that the proteome of FT grown in vitro in modified 
Mueller-Hinton broth differs significantly from that of FT cultured in cultured cells as 
opposed to FT cultured in brain-heart infusion broth, the latter of which closely 
resembles FT grown in cultured cells (75), we repeated the previously described study 
using FT cultured to mid-log phase in BHI broth and measured binding of plasminogen 
to the surface of FT. The results of this experiment indicated that the composition of FT 
culture media did not have a significant impact on the ability of FT to bind to 
plasminogen in FFP (Fig. 3.1). To confirm that binding of PLG to FT was a specific 
interaction involving exposed lysines, I also tested the ability of a lysine analogue and 
known inhibitor of PLG binding, ε-aminocaproic acid (εACA), to interfere with PLG 
binding to the bacteria. I found that εACA very effectively inhibited that ability of PLG to 
bind to FT. 
 
 
Binding of Purified Human and Murine PLG to FT LVS and FT Schu S4 
 
The plasma fraction of mammalian whole blood is a protein rich environment (60-
80 mg/mL in humans) which contains dozens of proteins and other molecules that are 
necessary for homeostasis.  To help eliminate the possibility of non-specific binding of 
PLG due to its high concentrations in human plasma (~200 μg/mL) and also rule out any 
interference from other plasma proteins, I used purified human Glu-PLG (PLG) in ELISA 
experiments similar to those conducted with FFP.  From these experiments with purified  
PLG I noted similar results to those observed when FFP was used (Figs. 3.1 and 3.2), 
which indicated that the binding of PLG required no other proteins from plasma. 
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Figure 3.1.  FT binds to PLG from human plasma. Microtiter plates coated with FT 
LVS cultured to mid-log phase in BHI broth were incubated for 1 hour with fresh frozen 
human plasma (FFP) in the presence or absence of 100 mM ε-amino caproic acid 
(εACA), a PLG-binding inhibitor.  A modified ELISA was performed to measure FT LVS-
bound PLG.  The results shown are representative of 3 experiments of similar design.  
Bars indicate +/- SEM in triplicate.  Statistical analysis was performed via one-way 
ANOVA using a Dunnett’s Multiple Comparison post-test (*** P < .001).    
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Figure 3.2.  Purified human plasminogen binds to FT.  FTLVS (Panel A) and 
FTSchuS4 (Panel B) were bound to microtiter wells and incubated for 2 hours with 
purified huPLG (3 μg/mL) in the presence or absence of 10 mM εACA). A modified 
ELISA was performed to measure FTLVS-bound huPLG. The results shown are 
representative of four (Panel A) and one (Panel B) experiments, respectively, of similar 
design. Bars indicate +/- SEM in triplicate. Statistical analysis was performed via one-
way ANOVA using a Dunnett's Multiple Comparison post-test (*** P < .001). 
 
 
14 
 
Although the attenuated FT LVS and highly virulent FT Schu S4 strains are genetically 
very similar, their abilities’ to cause disease are known to be quite different.   
 
Experiments comparing the PLG-binding ability of these FT strains were 
conducted to note any strain-dependant differences within our modified ELISA model. 
From the results of these experiments I determined that human PLG binds to the highly 
virulent Schu S4 strain of FT at moderately higher levels than observed with FT LVS 
(Fig. 3.2). Additional experiments using purified murine PLG confirmed similar binding to 
FT LVS and FT Schu S4 also, which suggests that this is property is not confined to only 
human PLG (Fig. 3.3). The binding of PLG/plasmin typically involves interaction with the 
exposed lysine residues of a ligand.  I confirmed that binding of PLG to FT is a lysine-
dependent interaction by showing that increasing concentrations of epsilon aminocaproic 
acid (εACA) can inhibit binding of PLG to FT LVS in a dose-dependent fashion (Fig. 
3.4).  Together, these data clearly indicate a typical plasminogen-binding reaction with 
FT in which lysine residues of the bacterial receptor(s) play a necessary role in the said 
interaction. 
 
 
Plasminogen Binds to the Outer Envelope of FT 
 
 In order for FT-bound PLG to both be activated to plasmin and also to be 
accessible to potential substrates, it would be important that the proenzyme be localized 
to the bacterial outer envelope of the bacterium. Therefore, I performed a series of 
experiments designed to determine whether PLG binds to the surface of FT. My first 
attempts to visualize PLG binding to the surface of FT involved the use of flow 
cytometric analysis. For these studies, FTLVS were pre-incubated in a PLG-containing 
solution, washed, and then labeled via sequential incubations with PLG-specific and a 
secondary antibody-fluorochrome conjugate. Unfortunately, I was unable to detect any 
PLG associated with FT using this technique. I posit that the failure of this technique was 
due to uncoupling of PLG:FT complexes due to shear forces associated with the fluidics 
system of the flow cytometer and/or the vortexing and centrifugation steps required for 
the washing steps during staining. I determined that a different technique that used 
much gentler washing and/or a formaldehyde fixation step would have a higher potential 
for success. 
 
As an alternative method for visualization of PLG binding to the surface of FT, I 
performed an immunohistochemical analysis of FT following incubation with PLG. For 
this study, FTLVS was incubated in a PBS solution containing 40 μg/mL human PLG 
and washed to remove unbound PLG, and then bacteria were immobilized onto a glass 
microscope slides via methanol fixation. PLG bound to FT was then labeled via 
sequential incubations with goat anti-PLG IgG and anti-goat IgG conjugated to DyLight-
488. I then visualized the localization of PLG on the surface of FT via confocal 
microscopy.  The images with PLG-coated FT in relation to uncoated bacterial controls 
clearly indicate a fluorescent signature which suggests that plasminogen binds to the 
outer envelope of FT (Fig. 3.5). I believe that this procedure proved successful because 
the washing steps performed on immobilized FT:PLG complexes were much gentler 
than those required for the flow cytometry-based approach. I also recognize that the 
methanol fixation step used in the protocol could have altered the integrity of the cell 
envelope, making it impossible for us to say with certainty that PLG binds to the true 
 outer surface of FT; I can only say that PLG binds to the outer envelope of the 
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Figure 3.3.  Purified murine plasminogen binds to FT.  FTLVS (Panel A) and 
FTSchuS4 (Panel B) were bound to microtiter wells and incubated for 2 hours with 
purified muPLG (3 μg/mL) in the presence or absence of 10 mM εACA. A modified 
ELISA was performed to measure FTLVS-bound muPLG. The results shown are 
representative of four (Panel A) and one (Panel B) experiments, respectively, of similar 
design. Bars indicate +/- SEM in triplicate. Statistical analysis was performed via one-
way ANOVA using a Dunnett's Multiple Comparison post-test (*** P < .001). 
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Figure 3.4.  Binding of human PLG to FT is inhibited in the presence of εACA. 
FT LVS was coated onto microtiter plate wells and incubated for 2 hours with purified 
human Glu-plasminogen (PLG) (3 μg/mL) in the presence or absence of titrated 
concentrations of εACA. The results shown are representative of 3 experiments of 
similar design.  Bars indicate +/- SEM in triplicate. Statistical analysis performed via one-
way ANOVA using a Kruskal-Wallis test determined a p-value of < 0.0001 relative to 
PLG incubated without inhibitor.  
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Figure 3.5.  Demonstration of bacterial surface localization of human PLG.   
Indirect immunofluorescence microscopy of PLG-associated FT LVS was performed as 
described in “Materials and Methods.”  Bound PLG ligand was detected using sheep 
anti-human primary antibody followed by incubation with Dylight-488 conjugated anti-
sheep/goat IgG secondary antibody.  Samples were visualized using a Zeiss LSM510 
confocal microscope on a Axiovert 100M base.   
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bacterium.  
 
 
Identification of Putative Francisella Plasminogen-binding Membrane Proteins 
 
    Because our ultimate goals are to define potential virulence factors and to 
identify any potential therapeutic or vaccine targets within the FT epitome, I sought to 
identify potential PLG receptors within the bacterial membrane.  The identification of 
putative PLG receptors on FT could potentially provide valuable targets for monoclonal 
antibody therapy or for immunization protocols to block these receptors from gaining 
access to this host protease and possibly limit any effects on its virulence. I wished to 
identify these PLG-binding FT proteins from the outer envelope protein fraction where 
they would most likely have the most effect on virulence in the host. To accomplish this, I 
utilized Sarkosyl soluble and insoluble FTLVS membrane fractions together with a Far-
Western blot method and mass spectrometry (Fig. 3.6).  Sarkosyl is a weak anionic 
detergent in which many outer membrane proteins of Gram-negative bacteria are 
insoluble (76), rendering them amenable to isolation by sedimentation via 
ultracentrifugation. After separation of these fractions by SDS-PAGE, the Sarkosyl-
treated proteins were then transferred to a PVDF membrane and then incubated this 
membrane with diluted PLG and identified bound PLG by reaction with anti-PLG (Fig. 
3.6A).  I used the relative migration rates of the reactive bands to identify the reactive 
proteins on a duplicate Coomassie-stained polyacrylamide gel (Fig. 3.6B), which were 
then excised for proteomic analysis by mass spectrometry.  Several prominent PLG-
binding proteins were noted in the total membrane fraction of FTLVS, all but one of 
which was found in the Sarkosyl insoluble fraction (Fig. 3.6B).  The identity of the 
prominent proteins from this assay (Fig. 3.6C) are the products of the following genes: 
FTL_1328 (outer membrane associated protein, fopA1), FTL_1042 (FKBP-type peptidyl-
prolyl cis-trans isomerase family protein), FTL_0336 (peptidoglycan-associated 
lipoprotein), FTL_0421 (hypothetical lipoprotein, lpn-A), and FTL_0645 (hypothetical 
lipoprotein).  In summary, through my experiments I was able to show that plasminogen 
is able to bind proteins found in the Francisella bacterial membrane fraction and 
putatively identify some of these receptors through Far-Western blotting methods and 
mass spectrometry.  
 
 
Discussion 
 
Within this chapter, assays were performed to evaluate the ability of Francisella 
tularensis to bind several host plasma proteins on its surface using fresh frozen human 
plasma.  To confirm our initial findings of PLG binding to the FT bacterial membrane as 
detected by a modified ELISA assay using FFP as a ligand source, an additional assay 
with purified PLG was performed which demonstrated similar results and confirmed 
those findings.  By including the plasminogen-specific binding inhibitor εACA with PLG in 
these experiments, this binding to FT was strongly inhibited.  This data suggests that the 
ability of FT to bind PLG was dependant on exposed lysine residues found within the 
protein receptors on both FT LVS and FT Schu S4.  Furthermore, I was able to identify 
several putative plasminogen receptors within a membrane fraction of FT.   
 
Until recently, FT has been considered an intracellular pathogen whose 
dissemination to tissues distal to the site of initial infection was highly dependent on its  
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Figure 3.6.  Identification of putative plasminogen-binding proteins of FT.  
Sarkosyl-soluble and insoluble protein fractions of FTLVS were separated by SDS-
PAGE and transferred to PVDF membrane. Membranes were then blotted with Glu-
plasminogen (3 μg/mL) followed by anti-plasminogen antibody and HRP-conjugated 
secondary antibody to detect plasminogen-binding proteins (Panel A). Protein bands on 
an identical Coomassie Blue-stained SDS-PAGE gel corresponding to those identified 
via blotting were excised (Panel B) and identified using proteomic methodologies (Panel 
C). The tryptic peptides identified via mass spectrometry that were used to identify the 
putative PLG ligands of FT are indicated in the peptide coverage maps (Panel D). 
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ability survive within host macrophages. The observation that FT can be found in  
high numbers in the acellular plasma fraction of its mammalian host (60-61) suggested 
that FT may have a significant extracellular component to its life cycle and that 
interactions between FT and one or more plasma proteins could contribute to its ability 
to survive and cause disease in the host. In fact, there are a number of examples of 
bacterial pathogens that utilize interactions with host plasma components to enhance 
their ability to gain entry to host cells and to penetrate the extracellular matrices of host 
cells/tissues.  Some examples of these bacterial pathogens and interactions with host 
plasma components will be discussed below in further detail. 
 
Complement and complement regulators are proteins found in plasma/serum that 
play an important role in host defense against pathogenic organisms.  The activation of 
complement in the presence of bacteria enhances the ability of the host immune system 
to clear these organisms, primarily mediated by opsonophagocytosis and the relatively 
chemotactic recruitment of phagocytic cells to areas of infection.  Factor H (FH) is the 
major complement regulatory protein which protects host cells from the actions of 
complement from the alternative, classical, and lectin pathways.  Most specifically, FH 
accelerates the degradation of C3b to an inactive form (iC3b) on the host cell surface, 
ultimately resulting in diminished C5-convertase formation and safeguarding self-cells 
from destruction. A wide range of bacterial pathogens (including Francisella) subvert the 
destructive mechanisms of complement by acquiring surface-bound complement control 
proteins.   Using ELISA and in vitro phagocytosis assays, Ben Nasr and Klimpel reported 
that both virulent and avirulent FT are able to bind C3-derived fragments for aiding in 
entry into monocytes and dendritic cells (63).  They were also able to show that FT could 
bind factor H from human serum and plasma by both Western-blot and flow cytometric 
analyses.  These authors suggested that acquisition of FH on the surface of FT may 
prevent the assembly of C5b-C9 membrane attack complex (MAC)(63).  The finding that 
FT could bind FH from human plasma caught my attention and led me to want to explore 
the possibility that other plasma/serum proteins from the host could also bind FT in ways 
that may be beneficial in its survival.  Besides factor H, a number of Gram-positive 
bacterial pathogens including streptococcal spp. (77-78), staphylococcal spp. (79-82), 
and Bacillus anthracis (83-84), as well as Gram-negative bacteria such as Borrelia spp. 
(85-87) have been shown the potential to augment their invasive capacity by interacting 
with such plasma proteins as fibrinogen, fibronectin, and/or PLG. Yersinia pestis is 
probably the most characterized example of a pathogen that exploits the host fibrinolytic 
system to penetrate host tissues. Yersinia expresses a surface serine protease 
(designated Pla) whose substrates include several complement components, PLG, and 
alpha2-antiplasmin (the primary circulating inhibitor of plasmin). Pla also has adhesin 
activity and binds to ECM preparations as well as purified laminin (a glycoprotein of 
mammalian basement membranes)(88). Because Pla upregulates plasmin activity, and 
because laminin is a substrate of plasmin, Yersinia can very efficiently penetrate 
basement membranes of host tissues (70, 89). Clearly, interaction with plasma 
components is a strategy that is used by many bacterial pathogens to gain a survival 
advantage within their hosts. 
 
It is well known that the binding of plasminogen to its ligand is primarily through 
recognition of lysine residues.   Though the inclusion of εACA in my in vitro experiments 
does not definitively prove that the lysine residues within the receptor proteins are 
necessary for binding of PLG to FT to occur, it is highly suggestive based on the 
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observed inhibition.  This interaction could of course be further studied by mutational 
studies.  However, to perform these studies it would be necessary to mutate each lysine 
residue in each putative PLG receptor protein.  This would be a labor-intensive endeavor 
which could also result in clones with many deleterious growth defects, making the 
recovery of every possible mutant a difficult and possibly futile effort.   Instead, a much 
easier approach to define the necessity of lysine residues on FT for binding PLG may be 
to simply modify them by using common biotinylation reagent kits and repeating the 
ELISA studies with the treated bacteria.  If by modifying all of these residues the ability 
of FT to bind PLG is diminished greatly, then this may provide even more supporting 
evidence to the inhibition data that I have shown.  These types of experiments could be 
included in further studies.  
 
Using a ligand-blotting technique coupled with proteomic methodologies I 
identified five FT LVS proteins that were able to bind to PLG, each of which are highly 
conserved among the various FT type A and B strains. Three of these proteins are 
lipoproteins (gene products of FTL_0336, FTL_0421, and FTL_0645). Two of the 
lipoproteins (fopA1 and lpnA) are unique to FT while the third, peptidoglycan-associated 
lipoprotein (PAL), is highly conserved among Gram-negative bacteria.  Interestingly, the 
specific use of surface-exposed lipoproteins as receptors for host PLG is not unusual 
and has been well documented in other human bacterial pathogens, such as some 
members of the genus Borrelia and Treponema.  Several members of the genus Borrelia 
use complement regulator-acquiring surface proteins (CRASP) to bind both PLG and 
complement factor H to aid in the ability of the organism to both disseminate and to 
resist innate immunity (90-95).  An additional example of a PLG-binding lipoprotein is 
OppA of Treponema denticola, which has been suggested to play a role in periodontal 
disease in humans (96).  With this in mind, there lies the possibility that lipoproteins of 
Francisella species may have the capacity to bind multiple host-derived proteins in 
addition to PLG.  
 
In summary, these results clearly show that PLG from host plasma has the ability 
to bind several FT membrane-associated proteins in a lysine-dependant manner.  
Further studies in this area of FT research may help better our understanding of its 
pathogenesis, especially as it pertains to the extracellular phase of its infection cycle.  
The next chapter focuses on both in vitro and in vivo studies aimed at characterizing the 
active protease, plasmin, on the surface of FT LVS.   
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CHAPTER 4.  DEMONSTRATION OF PROTEOLYIC ACTIVITY OF PLASMIN-BOUND 
FT LVS 
 
 
Introduction 
 
After internalization by host phagocytic cells, FT escapes into the cytoplasm 
before replication (45-46). Following bacterial replication in the cytoplasm, there is an 
induction of apoptosis (47-49) to enable its subsequent release into the extracellular 
environment for another cycle of infection. Though most work has focused on the 
intracellular aspects of FT infection, several reports have described the presence of 
many extracellular bacteria in mouse models of tularemia (60-61).  The significance of 
the extracellular life cycle phase of FT infection may yield valuable clues toward our 
complete understanding of its infectious cycle and ultimately contribute to a safe and 
effective vaccine against lethal tularemia.   
 
In the extracellular environment of the host, FT is known to interact with certain 
soluble protein components and uses these molecules to enable it to survive and 
replicate intracellularly, including complement proteins  (41-43), factor H (63), and 
surfactant protein A (97).  Most of all, these studies suggest that utilization of a variety of 
host-derived proteins may provide FT with a means to ensure its virulence capacity 
within a given host compartment, including plasma/serum. 
 
 In Chapter 3 I investigated the ability of FT to bind plasma proteins in an ELISA 
assay, and followed up on those findings by using purified plasminogen to confirm it as a 
putative ligand.  The ability of PLG to bind FT was also confirmed visually by means of 
confocal microscopy of ligand-coated bacteria and specific antibodies.  Furthermore, I 
used a ligand blotting technique coupled with proteomic methodologies to identify five 
putative plasminogen receptors from FT outer envelope preparations.    
 
The use of host coagulation/fibrinolytic system components by many types of 
bacterial pathogens to gain a survival advantage has been well documented for some 
time now (64-67).  For instance, the ability to acquire surface-associated plasmin has 
been studied as an important virulence mechanism in human pathogens such as Group 
A streptococci (68), Borrelia burgdorferi (69), Borrelia hermsii (86) and Yersinia pestis 
(70) by aiding in the organism’s ability to penetrate the extracellular matrix and to 
disseminate to distal sites in the host and beyond.  Work on Borrelia burgdorferi has 
even shown plasmin derived from the mammalian blood allows the pathogen to 
disseminate from the arthropod gut to the salivary glands, aiding in the transfer of these 
bacteria to another host at a subsequent feeding (69). Plasminogen (PLG) is a 92-kDa 
glycoprotein zymogen that is primarily involved in the degradation of clots (fibrin). 
Activation of this precursor protein by tissue-type (tPA) or urokinase-type (uPA) 
plasminogen activators converts it to an active serine protease (plasmin). Plasmin has 
an important role in blood clot resolution because of its role in the degradation of fibrin 
polymers. Plasmin has a broad-specificity, including many known substrates such as 
pro-collagenases, pro-metalloproteinases, and extracellular matrix proteins, such as 
fibronectin, laminin, and vitronectin.  Likewise, the ability of a bacterium to acquire 
surface associated plasmin can result in an enhanced ability of the pathogen to 
penetrate the extracellular matrix and disseminate to distal sites in the host (64, 66, 68). 
 
In order for plasminogen to be used as a virulence factor, the protein must be 
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activated by plasminogen activators found within the host or in some cases produced by 
the pathogen themselves.  This chapter outlines a series of experiments with the 
purpose of describing possible functions for the binding of PLG to the outer envelope of 
both attenuated (FT LVS) and virulent (FT Schu S4) subspecies of Francisella tularensis 
as seen in Chapter 3 and my published work (98). In this chapter, I provide experimental 
evidence that plasminogen which has been pre-bound to the outer envelope of FT can 
be cleaved to its enzymatically active form (plasmin) by treatment with a plasminogen 
activator, as evidenced by its ability to cleave both a chromogenic plasmin substrate and 
an extracellular matrix component (fibronectin). 
 
 
Plasmin Activation on the Surface of FT LVS In Vitro by a Plasminogen Activator 
 
   Francisella tularensis is well-known for its ability to disseminate to points distal to 
the route of entry and has recently been found extracellularly in high numbers in the 
plasma fraction of mice (60-61).  In several other bacterial systems, surface-bound PLG 
can be converted to its proteolytically active plasmin form and has been shown to 
contribute to the organism’s virulence by aiding in survival and enhancing tissue 
penetration in the host (64-67). To test whether PLG bound to FTLVS can be converted 
to plasmin, I first used a chromogenic plasmin substrate (H-D-Val-Leu-Lys-pNA) to 
detect proteolytic activity following the addition of a PLG activator (tPA) (Fig. 4.1).  I 
found that there is a plasminogen activator-dependant conversion of the chromogenic 
substrate which is based on the observed increase in absorbance readings at 405nm 
after cleavage of the plasmin-specific peptide sequence from its chromophore (p-
nitroaniline).  This finding not only indicates this is a possible mechanism in vivo, but 
also that there appears to be no intrinsic plasminogen activator produced by FT based 
on a lack of substrate conversion in a control reaction that lacked tPA.   
 
Some examples of potential substrates for plasmin-bound bacteria, including FT, 
are components of the extracellular matrix (ECM). To determine whether FT-bound 
plasmin could potentially participate in the breakdown of extracellular matrices, I allowed 
PLG to bind to the surface of FT, activated it via treatment with tPA, and then tested the 
ability of the FT surface-bound plasmin to use fibronectin, an ECM component, as a 
proteolytic substrate (Fig. 4.2).  These results demonstrate plasminogen bound to the 
surface of FT can be converted to its active form, plasmin.  This active serine protease 
can proteolytically degrade fibronectin, and potentially other protein components of 
extracellular matrices. 
 
 
Murine Infection with FT LVS-pLux with the Inclusion of a Plasminogen Binding 
Inhibitor 
 
 The acquisition of plasmin on the surface of bacterial pathogens has been shown 
in numerous examples to increase their potential virulence and dissemination within 
mammalian hosts (64-67).  Based on our findings of the ability of FT to bind and allow 
the activation of plasmin on its surface in vitro, I hypothesized that if 
plasminogen/plasmin was unable to bind to the outer envelope of FT LVS during the 
course of infection, then it may be possible to observe signs of reduced disease severity. 
To test this, I performed an in vivo dissemination study using the IVIS whole animal  
imaging system.  This experiment was performed by employing FT that had been 
engineered to express light (FT LVS-pLux) and a treatment group that received a series 
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Figure 4.1.  FT surface-bound plasminogen can be converted to plasmin. FT LVS 
was incubated with purified human plasminogen (PLG) at a concentration of 96 μg/mL.  
After removal of unbound plasminogen, a chromogenic plasmin substrate (D-VLK-pNA), 
tissue plasminogen activator (tPA), or both were then added to test the proteolytic ability 
of each sample preparation. Conversion of the chromogenic substrate was measured by 
comparison of ∆405 nm. The results shown are representative of 3 experiments of 
similar design.  Bars indicate +/- SEM in triplicate. Statistical analysis was performed via 
one-way ANOVA using a Dunnett’s Multiple Comparison post-test (*** P < .001).  
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Figure 4.2.  Fibronectin is a substrate for plasmin bound to FT.   FTLVS (109 CFU) 
were incubated with 100 μg of purified human PLG and 0.5 μg tissue tPA for 1 hour at 
37˚C.  After removal of unbound PLG and tPA, 3 µg fibronectin was added and allowed 
to incubate for 24 hours at 37˚C.  Supernatant from each preparation were separated by 
SDS-PAGE and transferred to PVDF membrane.  Degradation of fibronectin was 
detected by Western blot analysis. 
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of εACA infusions that could potentially prevent the binding of plasminogen to the 
surface of FT.  I hoped that by using FT LVS-pLux it would enable us to use the 
luminescent signal as a possible means to visualize any changes in distribution of the 
bacteria in the mice over time that plasminogen inhibition may cause.  Female Balb/c 
mice (5/group) were infected intranasally (i.n.) with 1x106 CFU FT LVS-pLux while under 
light anaesthesia. In addition, six hours before infection and every six hours for the 
duration of the experiment, mice were injected intraperitoneally with 200 μL of εACA 
(150 mg/mL) or sterile PBS alone to evaluate the effects that a plasminogen binding 
inhibitor may have on disease progression.  These mice were weighed prior to infection 
and every day for the course of the experiment to monitor the progressive weight loss 
that is caused by FT infection.  As expected there was a dramatic loss of weight in the 
FT LVS-pLux-infected mice as compared to those that were mock-infected with PBS 
only (Fig. 4.3).  Comparison of the FT LVS-pLux infected groups that received injections 
of εACA showed only an insignificant reduction in weight loss at day 6 as compared to 
mice that were given PBS only.  To look for differences in the distribution of luminescent 
FT bacteria through the course of this experiment, images of lightly anaesthetized mice 
were collected using a Xenogen IVIS system (Fig. 4.4).  Analysis of these images 
revealed no obvious differences in the distribution of FT in this murine infection model 
with or without i.p. injections of the plasminogen inhibitor.  All but one mouse in the FT-
infected group receiving εACA survived to the sixth day, at which all remaining mice 
were sacrificed due to the severity of infection. 
 
Discussion 
 
Infection with Francisella tularensis is often associated with bacterial 
dissemination to sites distal to the primary entry point.  Most of what is known about FT 
pertains to its intracellular phase of infection, whose dissemination to tissues distal to the 
site of initial infection was highly dependent on its ability survive within host 
macrophages. Recently, the detection of high numbers of extracellular FT in the acellular 
plasma fraction of mice (60-61) suggest that FT may have a significant extracellular 
component to its life cycle and that interactions between FT and one or more plasma 
proteins could contribute to its ability to disseminate within the host. Results from our 
ELISA and confocal microscopy experiments detailed and discussed in Chapter 3 
provided evidence of the ability of FT to bind PLG and the identity of several putative 
bacterial plasminogen receptors from a membrane protein fraction.   
 
One well-documented and relatively common method for bacteria to disseminate 
and avoid the host innate immunity is through the acquisition of host 
plasminogen/plasmin on its surface (64-67).  In this chapter I showed that plasminogen 
bound to the surface of FT could cleave a plasmin-specific chromogenic substrate, thus 
demonstrating its proteolytic potential.  I also showed by Western-blot analysis the 
degradative effect that plasmin-coated FT LVS had on an extracellular matrix 
component, fibronectin.  This observation is not at all unique to FT and similar findings 
are in the literature for several other bacterial pathogens to date (69, 83, 99-100).  These 
findings support our hypothesis that the ability of FT to bind to serum plasminogen may 
enhance its ability to penetrate extracellular matrices, however, more in-depth studies of 
this potential virulence factor needed to be performed in vivo to firmly establish that FT’s 
ability to bind to plasminogen offers a survival advantage to this highly pathogenic 
bacterium. 
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Figure 4.3.  Daily weight measurements of Balb/C mice after intranasal infection 
with FT LVS-pLux.  Female Balb/C mice were infected intranasally with 1x106 CFU of 
(~1,000X LD50) luciferase-expressing FT LVS (FT LVS-pLux).  Before and during the 
course of infection, mice were given intraperitoneal injections of εACA or PBS alone 
every six hours.  Mice were weighed daily as a measure of disease progression, and the 
results are reported as percentage of starting weight. 
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Figure 4.4.  Murine infection with FT LVS-pLux with intraperitoneal εACA 
injections.  Female Balb/C mice were infected intranasally with 1x106 CFU of (~1,000X 
LD50) luciferase-expressing FT LVS (FT LVS-pLux).  Before and during the course of 
infection, mice were given intraperitoneal injections of εACA or PBS alone every six 
hours.  Dissemination of FTLVS-pLux was monitored daily via whole animal live imaging 
using an IVIS Spectrum imaging system. Exposure times varied based on luminescent 
signal intensities in an effort to collect between 600 and 60,000 counts, and image 
scaling was normalized by converting total counts to photons/second. 
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If FT can bind plasmin on its surface, then this active protease could contribute to 
the distribution of this bacterium through the course of tularemia.  It an effort to test this 
hypothesis in vivo, I administered a plasminogen-binding inhibitor (εACA) every six 
hours to mice that had been infected with a lethal dose of FTLVS-pLux (1,000 X LD50) 
and monitored disease progression by monitoring outward clinical symptoms, weight, 
and actual bacterial distribution patterns via whole live animal imaging. Unfortunately, I 
observed no significant differences in disease progression relating to treatment with 
εACA. At the time of my in vivo experiment, I found only one published work which 
utilized εACA in an influenza virus infection model (72), and none featuring the 
numerous bacterial pathogens that are known to interact with plasminogen.  However, 
during the writing of this manuscript, a paper was published that used εACA to inhibit 
plasminogen in a staphylococcal infection model found that this drug actually increased 
the severity of disease and decreased the time to death relative to mice receiving 
injections of PBS only.  Based on these findings, one may speculate that the inhibition of 
plasminogen/plasmin, or that εACA itself, has an unknown detrimental effect upon the 
innate immunity of the host that may negate any impairment caused on the virulence of 
the pathogen(s). Neutrophils and monocytes are an important line of defense against 
bacterial infection, and it has been shown that the activation of these cell types 
increases the number of plasminogen binding sites on their surface (101-103).  Though 
the function of plasminogen bound to the surface of neutrophils and monocytic cells is 
not very clear, it is possible that the presence of a plasminogen inhibitor such as εACA 
may uncouple some important function(s) needed to clear bacterial pathogens such as 
FT.   
 
Here I have shown that FT LVS can bind to PLG and that surface-bound PLG 
can be activated by tPA to its proteolytic form (plasmin). The binding of PLG on the 
surface of FT could play a role in several phases of tularemia, including the initial entry 
into the host through insect bites and/or broken skin where active fibrinolytic processes 
would provide an early opportunity for FT to acquire proteolytic activity that might 
augment the establishment or dissemination of infection.  During later phases of 
tularemia the acquisition of plasmin on the cell surface may contribute to its 
pathogenicity by degrading host innate effector molecules and extracellular matrix 
components. Based on the new report that FT-bound plasmin can degrade 
immunoglobulins (104) as well as the established ability of FT to acquire surface-bound 
factor H (63), it also appears likely that FT uses plasma components to interfere with 
host humoral immune mechanisms throughout the course of FT infection. Future studies 
to identify additional plasma components that can be surface acquired by FT may 
uncover novel virulence mechanisms used by this pathogen during its extracellular life 
cycle.  
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CHAPTER 5.  GENERAL DISCUSSION 
 
 
Summary 
 
Our current understanding is that following entry through broken skin or mucus 
membranes, Francisella tularensis (FT) is taken up by resident phagocytic cells before 
disseminating throughout the host.  These FT-infected cells are believed to travel by 
means of lymphatic vessels and finally replicating in the draining lymph nodes as well as 
major organs such as the lungs, spleen, and liver.  Besides being found inside host cells, 
FT can also found in surprising numbers as extracellular bacteria during later stages of 
tularemia (60-61).  As might be expected, being in contact with host plasma proteins 
outside of the cell leaves FT exposed to components of innate immunity, such as 
complement proteins, antimicrobial peptides, and various opsonizing proteins.  Despite 
all of these potential killing mechanisms of the mammalian host, FT appears not only 
resistant to these threats (41, 97, 105), but in some instances has been shown to use 
such host proteins to its advantage.  In one such example, it has been suggested by Ben 
Nasr and Klimpel that FT circumvents the assembly of the complement membrane 
attack complex on its surface while enabling complement-mediated opsonophagocytosis 
by using host factor H (63).  FH protects host cells from activation of complement via the 
alternative pathway by recognition of sialic acid and other polyanions present on the 
mammalian cell surface (106).  An affinity for sialic acid/polyanions helps direct FH 
activities toward mammalian cells, which is absent on the surface of most bacteria, thus 
providing a way for FH to discriminate host from pathogen.  The binding of FH to the 
host cell surface dissociates C3bBb and makes C3b susceptible to factor I-mediated 
cleavage.  Similar complement aversion mechanisms are not only found in FT, but other 
bacterial pathogens such as Streptococcus pyogenes (107), Haemophilus influenza 
(108), Neisseria gonorrhoeae (109), Neisseria meningitidis (110),  and Borrelia spp (93, 
111).  These bacteria have been shown to express receptor molecules that allow them 
to exploit the action of FH and other complement inhibitors thereby increasing their 
survivability in the host extracellular environment.  Interestingly, a study utilizing 
monoclonal antibodies directed against a factor H binding protein (GNA1870) from N. 
meningitidis has demonstrated a bacteriocidal effect in the presence of human serum 
(112), underlining the necessity of this host protein for its survival in the extracellular 
environment.   
 
Besides components related to the complement pathways, many bacterial 
pathogens have previously been shown to utilize host plasma proteins such as 
plasminogen/plasmin to increase dissemination and/or subvert innate immune 
responses in the host (64-67).  Because there is a lack of published work on FT 
interactions with host plasma proteins, I first sought to determine whether certain 
proteins that are commonly used to enhance virulence (fibrinogen, fibronectin, and 
plasminogen) have a significant binding affinity for this bacterium.  In Chapter 3 I 
described ELISA assays in which I was able to confirm the association of factor H, 
fibronectin, and plasminogen with FT-coated microtiter plates after incubation with 
human fresh frozen plasma (Appendix A).  Because the binding of a protease to the 
bacterial outer envelope has the potential to increase pathogenicity within the host, I 
chose to focus our efforts on characterizing the plasminogen:FT interaction.  
 
A wide variety of bacterial pathogens are known to utilize plasminogen/plasmin in 
ways thought to aid in their survival and dissemination within the host extracellular 
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environment.  The type of plasminogen receptor proteins used by these bacteria exhibit 
tremendous diversity, ranging from the surface exposed lipoproteins (B. burgdorferi) to 
glycolytic enzymes such as glyceraldehydes-3-phosphate dehydrogenase and α-enolase 
(Group A streptococci) (64, 113-114).  PLG is well-known for its affinity to lysine residues 
on the surface of protein receptors.  Our work clearly showed that plasminogen binding 
to FT could be inhibited by the inclusion of the lysine analog, epsilon aminocaproic acid 
(εACA) in our ELISA experiments, indicating the involvement of lysine residues in 
binding to these bacterial receptors.  Furthermore, I was able to identify several putative 
plasminogen receptors from a FT LVS membrane fraction through Far-Western blotting 
approach and proteomic identification.  
 
In order for plasminogen to be converted to its active form (plasmin), it must be 
activated by plasminogen activators, such as tissue type plasminogen activator (tPA).  
Because this is also relevant in the case of PLG on the bacterial outer envelope, I 
decided to test the ability of FT to activate bound PLG in a set of experiments.  By using 
a chromogenic plasmin substrate, I demonstrated the ability of plasminogen to be 
converted to an active protease on the bacterial outer envelope in the presence of tPA.  
The presence of plasmin on the surface of pathogenic bacteria such as Borrelia spp is 
known to enhance their ability to penetrate the extracellular matrix and augment 
dissemination/tissue penetration within the host (115-118).  When plasmin-coated FT 
bacteria were incubated in the presence of fibronectin, a component of extracellular 
matrices (ECM), it clearly demonstrated proteolytic cleavage of this substrate in my 
experiments in vitro.   
 
Finally, because it is unknown how the inhibition of PLG binding to FT in vivo 
might affect the observable aspects of lethal tularemia, I sought to try and answer this 
question in a murine model.  I conducted an in vivo experiment by infecting εACA-
injected mice with FT LVS-pLux, but was unable to prevent lethal infection or detect any 
significant changes in disease progress with this treatment.  This result was not too 
surprising considering the multiple functions of plasmin within the context of overall 
homeostasis. In addition, since this type of treatment has yet to be shown as an effective 
means to inhibit the disease-causing potential of other known plasmin-binding 
pathogenic bacteria, it is possible that other infection models failed to respond positively 
to plasminogen inhibition.    
 
 
Binding of Human Plasma Proteins to FT and the Identification of Putative 
Receptors 
 
 The first experiments presented in this work involved incubating human FFP with 
FT bound to ELISA plates.  This was done primarily to screen for possible interactions 
with known and unknown plasma/serum proteins (fibrinogen, fibronectin, plasminogen) 
by detection with antibodies specific for each antigen.  These particular plasma proteins 
were chosen because of their established roles in aiding survival and/or dissemination in 
other bacterial pathogen models.  Since it was known that factor H is able to bind FT 
(63), this served as an appropriate positive control.  Using a modified ELISA assay, 
human PLG was shown to bind significantly to the immobilized FT bacteria.  Similar 
ELISA experiments using purified human and murine PLG instead of whole plasma 
revealed that binding to FT was independent of any other host protein and also not a 
host-specific interaction.  In addition, the ELISA experiments with purified PLG (3 µg/mL) 
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detected binding to FT at a concentration far lower than might be found in whole plasma 
(~200 μg/mL for humans). 
 
 Following up on my experiments with FT LVS, I then wanted to assay the ability 
of PLG to bind a more virulent subspecies of FT.  My results revealed that the binding of 
PLG to FT was shown to occur in both the attenuated FT LVS and highly virulent FT 
Schu S4 subspecies.  Interestingly, my ELISA data appears to show a slightly higher 
amount of both human and murine PLG binding to FT Schu S4 in relation to FT LVS.  
These results were in agreement with a report that was published very recently by 
Crane, et al (104).  Within this report the authors noted an interesting effect on 
opsonization after treatment with PLG by which the active protease degraded anti-FT 
IgG molecules, resulting in decreased uptake of virulent, but not avirulent FT by 
macrophages. Their results indicated an ability of highly virulent FT to bind greater 
amounts of PLG/plasmin relative to the less virulent FT LVS.  Additionally, their work 
also showed that only FT Schu S4, but not FT LVS, could bind the active form of the 
protease (plasmin).  These experiments were conducted by adding a plasminogen 
activator (uPA) together with plasminogen for the detection of bound ligand as opposed 
to adding plasminogen alone. Together these data open the possibility that having 
plasmin on the outer envelope of FT could play a role in the ability of those subspecies 
to have increased survivability and/or invasiveness in the host by decreasing the number 
of these bacteria that are taken up by host phagocytes.   
 
 Because the localization of FT-bound PLG would likely require surface exposure 
to allow its activation to plasmin by host plasminogen activators and also for proteolytic 
activity to occur, I then performed confocal microscopy experiments with pre-coated 
bacteria.  FT LVS that were allowed to incubate in the presence of human PLG, washed, 
and then fixed to glass coverslips were then used to detect this ligand on the bacterial 
outer envelope.  By using a fluorescently labeled secondary antibody, confocal 
microscopic analyses suggest that PLG does indeed bind to the surface of FT.  However 
it remains a possibility that some of the staining observed was the result of PLG 
penetration into the FT outer envelope via lipid mixing caused by the methanol fixation 
step. An attempt to get around this fixation step through the use of flow cytometry proved 
unsuccessful, possibly due to the effect of sheer forces displacing the fluorescently-
labeled PLG from the bacterial outer envelope.  Perhaps cross-linking of bacterial 
surface-bound PLG with formaldehyde or glutaraldehyde prior to antibody staining may 
resolve this issue for future studies by flow cytometry.   
 
Many bacterial pathogens have previously been shown to utilize host 
plasminogen/plasmin to increase tissue invasion and subvert innate immune responses 
in the host.  Within this broad range of bacterial species lies an equally diverse group of 
unique membrane and cytoplasm-associated plasminogen receptors that have been 
identified (64-67).  Because the identification of PLG receptors in FT may provide us with 
potential therapeutic or vaccine targets, I set out to try and identify these proteins from 
membrane factions. Our SDS-PAGE/Far-Western blotting experiments and the 
subsequent mass spectrometric identification of the most prominent FT LVS PLG-
binding membrane proteins resulted in the identification of five putative PLG receptors:    
peptidoglycan-associated lipoprotein (FTL_0336),  lpnA (FTL_0421),  a hypothetical 
lipoprotein (FTL_0645), FKBP-type peptidyl prolyl cis-trans isomerase family protein  
(FTL_1042), and fopA1 (FTL_1328).  I found it interesting that two of the identified PLG 
receptors, fopA1 and lpnA, are poorly characterized and both highly conserved 
lipoproteins that are unique to FT. One very recent study reported an increase in the 
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survival of mice that had been intradermally infected with FT LVS and later passively 
immunized with anti-fopA and anti-lpnA monoclonal antibody preparations (119).  
Whether or not the observed increase in mouse survival from tularemia in those 
experiments is related to the antibodies’ ability to block PLG or other plasma proteins 
from binding to receptor sites cannot be determined at this time, but should be 
considered in future studies. 
 
 
Plasminogen Bound to the Surface of FT LVS Demonstrates Proteolytic Abilities 
in the Presence of a Plasminogen Activator 
 
Though the intracellular phase of FT infection has been well-documented, the 
recent reporting of high numbers of extracellular bacteria during tularemia brings to light 
the potential interaction of this pathogen with host plasma proteins. Our previously 
described experiments in Chapter 3 sought to characterize the ability of FT to bind any 
of several plasma proteins that are known to be used by pathogenic bacteria to increase 
their virulence and/or tissue invasion within the host.  Following an ELISA-based 
screening experiment using human plasma, the detectable binding of plasminogen drew 
our attention because of the potential benefits to virulence in having this host protease 
zymogen bound to its outer envelope.  Because any benefit of having the zymogen form 
of this protein bound to the outer envelope is limited by its ability to be converted to an 
active protease by a plasminogen activator, I sought to further characterize the 
proteolytic potential of PLG-coated FT bacteria.   
 
The first set of experiments to measure plasmin activation involved incubating 
PLG-coated bacteria in the presence of tissue type plasminogen activator (tPA) and a 
plasmin-specific chromogenic substrate (D-VLK-pNA).  When this plasmin substrate is 
cleaved of its peptide moiety by the active protease, it in turn causes the development of 
a yellow color that can be measured by an increase in the spectrophotometric 
absorbance of the attached chromophore, p-nitroaniline (pNA), at 405 nm relative to 
controls lacking one or more necessary components.  Our results clearly indicated the 
generation of a significant amount of plasmin activity when PLG-coated FT LVS were 
incubated in the presence of both tPA and this plasmin-specific substrate, which showed 
a three-fold increase in absorbance at 405 nm relative in relation to PLG-coated bacteria 
that lacked tPA.  Based on these findings, I concluded that not only is plasminogen able 
to bind the surface, but that it is also possible to generate the active form of this enzyme 
(plasmin) which may also degrade known host protein substrates. 
 
Next, in order to test the ability of plasmin-coated FT to degrade a host protein 
found in the ECM, I conducted experiments to look at the ability of these proteolytically 
activated bacteria to degrade fibronectin.  By incubating plasmin-coated FT LVS with 
purified fibronectin, I was able to show through Western-blot analysis that these treated 
bacteria clearly possessed a proteolytic affect upon this substrate.  This opens the 
possibility that FT could use the ability of plasminogen/plasmin acquisition on its surface 
to aid in the ability to both penetrate the ECM to disseminate more easily in the host and 
to avoid the effect of active and passive immune responses.  Direct evidence of the 
contribution of plasminogn/plasmin to tissue penetration in the host is difficult to prove in 
vivo, but some in vitro models have been used. These types of assays have been 
performed in other well-studied plasminogen-utilizing pathogens within the genus 
Borrelia. Coleman et al has shown in their work where plasmin-coated B. burgdorferi 
have the ability to penetrate endothelial cell layers in vitro (115).  By using an in vitro 
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model of the blood-brain barrier, B. burgdorferi has demonstrated its ability to cross this 
cell layer in the presence of plasminogen (117). Though rare, cases of tularemia 
meningitis are present in the literature and this may represent an interesting example of 
how FT could cross ECM barriers to gain access to less hostile environments such as 
the central nervous system (120-126).  However, as this is obviously an inappropriate 
experiment in humans, further studies on the possible contribution of plasmin to 
tularemic meningitis would require the development of an appropriate animal model of 
infection which is currently unavailable at this time.  In all, these data suggest that the 
binding of plasminogen by FT has the potential to augment its ability to penetrate tissue 
barriers in the host. 
 
The generation of plasmin on the surface of FT has recently been shown by 
Crane et al to decrease both the opsonization of FT-specific antibodies as well as the 
opsonophagocytosis of these bacteria by phagocytic cells (104).  Most importantly, their 
findings also indicate that plasmin has a proteolytic effect on immunoglobulins, which 
they state may help explain the inability of humoral immunity alone to prevent lethal 
infection with virulent strains of FT (104).  I feel that their report helps to support our 
findings in outlining some of the possible ways in which plasminogen/plasmin bound to 
the outer envelope of FT could augment the survivability and perhaps the invasiveness 
of this bacterial pathogen in vivo.  
 
 
Murine Tularemia Studies with the Inclusion of a Plasmin Inhibitor 
 
Our previous studies described experiments which provided evidence of 
plasminogen’s ability to bind the surface of both a virulent and an attenuated strain of FT 
and provided the identification of putative receptors from its membrane fraction.  Within 
those experiments I showed how this binding of plasminogen to FT could be inhibited in 
the presence of a lysine analog (εACA).  I also provided experimental evidence of the 
activation of plasminogen to plasmin on the bacterial outer envelope and a 
demonstration of its proteolytic potential on an ECM component, fibronectin.  
 
Because it is unknown how the inhibition of PLG binding to FT in vivo might 
affect any directly observable aspects of lethal tularemia such as weight loss, survival, 
and bacterial distribution, I sought to try and answer this question in a murine model.  I 
approached this question by conducting an in vivo experiment by giving regular doses of 
the plasminogen inhibitor εACA to naïve Balb/c mice before and during a lethal 
challenge with FT LVS-pLux.  I chose to use FT LVS-pLux for the infection because this 
method would allow us to track the bacteria by capturing luminescent images of live 
animals through the course of infection by using the Xenogen IVIS photodocumentation 
system.   
 
Unfortunately I was unable to prevent lethal infection or detect any significant 
changes in disease progress with FT-infected mice that had received the plasminogen 
inhibitor or PBS alone.  The weight-loss curves and times to death were essentially the 
same for both infection groups, thereby leaving the in vivo effects of plasminogen-bound 
FT indeterminable by our method.  This was not too surprising considering the multiple 
functions of plasmin within the context of overall homeostasis and that this type of 
treatment has yet to be shown as an effective means to inhibit the disease-causing 
potential of other known plasmin-binding pathogenic bacteria.  In fact, there has been a 
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report on a murine staphylococcal infection model that describes an increase in disease 
severity while administering regular doses of a closely related lysine analog, tranexamic 
acid.  It is possible that these types of experiments have been tried with other plasmin-
utilizing pathogenic bacteria and not reported because they also failed to yield significant 
results.  
 
Perhaps the pleiotropic functions of plasmin in the host are too complex to simply 
inhibit them all completely.  In considering this possibility, a more direct approach should 
be used in the context of studying its affect on the course of tularemia infection to avoid 
interfering with other processes in the host.  In one example, plasmin-dependent 
metalloproteinase-9 activation has been found necessary for macrophage recruitment to 
sites of inflammation (127).  It is possible that inhibiting plasmin activity in my in vivo 
experiments resulted in a decrease in the infiltration of phagocytes to sites of FT 
infection.   Being that phagocytic uptake of FT is an important step in clearance of these 
organisms, the use of plasminogen inhibitors may not be the best choice for future 
studies.  A more suitable method for preventing plasminogen/plasmin binding specifically 
to the outer envelope of FT may be found by the use of monoclonal antibodies against 
the identified plasminogen receptors that I have identified.  This may be a consideration 
for future studies in the matter.  
 
In conclusion, I hope that these studies have brought to light another aspect to 
consider in developing safe and effective treatments and vaccines against infection with 
Francisella tularensis. Published works describing the extracellular phase of FT infection 
are now coming to light and the possible contributions of plasminogen/plasmin during 
this phase should not be ignored (Fig. 5.1).  Though not likely to be a major contributor 
towards its pathogenicity, further studies on the ability of FT to acquire plasmin may 
reveal that this process works in concert with other known or unknown virulence factors 
during tularemic infection. 
 
 
Future Directions 
 
  Because of my work and that of others, we now know that FT is able to interact 
with at least two host plasma/serum components (factor H and plasminogen) and that 
these proteins may contribute in some degree to its virulence and survivability within the 
host.  However, expanding upon the experiments presented in this work may be 
necessary to define clear roles, especially in vivo.   
 
 My in vivo experiments utilizing the lux-expressing strain of FT sought to 
determine changes in the distribution of bacteria following an intranasal challenge during 
treatment with a plasminogen inhibitor.  Perhaps variations on this experiment could be 
designed that focus on other routes of infection which could be used to more accurately 
determine the effects of plasminogen binding to FT.  One problem with my in vivo 
infection model was that by giving the bacteria intranasally it is extremely difficult to 
ensure that all FT remained in contact with the respiratory tract and are not swallowed.  
This brings to question whether the intended CFUs delivered for this route were indeed 
the same between any two mice. 
 
A second problem with the original in vivo model lies in the diminishing signal 
from the bacteria at day 0.  Being that such few bacteria are delivered and that they 
must travel from the nares to various parts of the respiratory tract, the dilution of 
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Figure 5.1.  Diagram summarizing the potential roles that plasminogen may play 
during FT infection. Both examples of early and late stages of FT infection occur within 
plasminogen-rich environments.  It is within damaged tissue and/or blood where FT 
would be likely to acquire plasmin on the outer surface.  This protease-bound pathogen 
could then aid in the degradation of host proteins, as indicated in recently published 
work.  Further work is needed to describe the in vivo effects of this process.  
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signal at this point removes a potentially important data point.  Entry into the host could 
be the first opportunity for FT to encounter available plasminogen and changes in the 
distribution of bacteria at the initiation of infection would be difficult to discern with this 
methodology.  
           The third and most important variation on this line of experimentation lies in the 
use of appropriate routes of infection for measuring the effects of plasminogen on FT 
infection.  To measure the effect(s) of FT with the ligand we may want to ensure contact 
with plasminogen throughout the initial point of infection.  This goal may better be 
attained by placing the bacteria within the tissue as opposed to infecting mice by a 
mucosal surface as found in the respiratory tract.  It is unclear how much plasminogen 
may be encountered via the respiratory route and this may be inviting error into the 
interpretation of results from the very start of the experiment. 
 
 One way to possibly resolve these issues could be to use an intradermal or 
subcutateous infection model.  This route may be advantageous to the goals of this work 
for several reasons.  First, by giving the bacteria under the skin the lux signal will be 
more concentrated and have less tissue to absorb the light, thus improving the resolution 
of an initial infection image.  Second, both the distribution and intensity of signal away 
from the injection point could more accurately be used to gauge changes induced by 
inhibitors or the pre-coating of bacteria with plasminogen.  It is possible that a 
quantifiable change in the diameter of the luminescent might show differences between 
groups of mice.  Finally, this route most closely resembles a more naturally occurring 
infection (arthropod vector or entry through broken skin) and may be more appropriate in 
a general manner.  Establishing this method might then allow one to closely measure 
changes in tissue penetration/dissemination of FT while treated with plasminogen 
inhibitors.  Alternatively, these experiments could be used to compare different mouse 
strains or PLG knock-out mice to look for changes in the distribution of FT by 
intradermal/subcutaneous routes. 
 
 Other experiments may include ways to address the importance of FT surface 
lysine residues in binding PLG on its surface.  As discussed in Chapter 3, mutating each 
lysine on the bacterial surface would be a near impossibility if one wished to recover 
each and every mutant clone.  Luckily, biotinylation kits are commercially available that 
allow the user to modify lysine residues on proteins by reacting them with biotin.  This 
simple and effective method may allow us to essentially block the kringle domains of 
PLG from binding lysine on the bacterium.  These lysine-blocked bacteria could then be 
coated onto ELISA plates and experiments could be performed as mentioned previously 
in this work to show its effect on PLG binding.  A loss of signal in these experiments 
would provide further evidence for a dependence of lysine in the FT-PLG binding.  An 
additional experiment with the same lysine-blocked FT could be used in a Far-Western 
blot format to show a loss of PLG binding to bacterial surface proteins.  However, one 
would have to consider the increase in molecular weight and how this would affect the 
migration rate of the modified FT proteins during SDS-PAGE.    
   
Aside from plasminogen, other host-derived proteins should also be considered. 
Given the multitude and quantities of available host proteins in blood and other fluids, it 
is unlikely that we have found all cases where FT may use host proteins and other 
molecules to its advantage.  Though only briefly mentioned in this work, soluble 
fibronectin was also positive for binding to FT in our preliminary ELISA screening 
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method with a single putative receptor protein being identified (Appendix B).  The ability 
of bacterial pathogens to bind fibronectin has been studied  in such infection models as 
Pseudomonas aeruginosa (128), Borrelia burgdorferi (85, 129) , and has been well 
documented in Gram-positive cocci (130-131) as a means for adherence and uptake of 
these organisms into host cells. It is possible that FT uses a similar mechanism to enter 
non-phagocytic cells, which is another set of experiments that should be considered for 
future work.  Additionally, the FT culture filtrate components that were identified in my 
previous work (Appendix C) might also interact with host molecules and should be 
taken into account in future studies as well. 
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APPENDIX A.  PRELIMINARY FT SCREENING ASSAYS USING HUMAN PLASMA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1 Preliminary FT screening assays using human plasma.  Microtiter plates 
coated with FT LVS cultured to mid-log phase in MMH or BHI broth were incubated for 1 
hour with fresh frozen human plasma (FFP).   A modified ELISA was performed to 
measure FT LVS-bound ligands as indicated.  The results shown are representative of 2 
experiments of similar design.  Bars indicate +/- SEM in triplicate. 
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APPENDIX B.  IDENTIFICATION OF A PUTATIVE FIBRONECTIN-BINDING PROTEIN 
FROM FT 
 
 
Figure B.1. Identification of a putative fibronectin-binding protein from FT.  A 
Sarkosyl- insoluble protein fraction of FTLVS was separated by SDS-PAGE and 
transferred to PVDF membrane. Membranes were then blotted with human fibronectin (3 
μg/mL) followed by sheep anti-fibronectin antibody and HRP-conjugated anti-sheep IgG 
secondary antibody to detect fibronectin-binding proteins (Panel A). Protein bands on an 
identical Coomassie Blue-stained SDS-PAGE gel corresponding to those identified via 
blotting were excised (Panel B) and identified using proteomic methodologies (Panel C) 
with the indicated peptide coverage map (Panel D). 
 
 
54 
 
APPENDIX C.  STUDIES USING FT LVS CULTURE FILTRATE PREPARATIONS AS 
AN IMMUNIZATION AGAINST TULAREMIA 
 
 
Summary and Purpose 
 
Francisella tularensis (FT) is the causative agent of a life-threatening disease 
known as tularemia.  The high virulence and low inoculum needed to cause tularemia 
led several countries to pursue the development of Francisella as a biowarfare agent 
starting in the 1930’s and is a high-priority organism in anti-bioterrorism research.  
Incomplete understanding into the details of its pathogenicity have complicated 
immunoprotection studies for countering an FT infection and have led many researchers 
over the years to examine the successful vaccination strategies used for other 
pathogenic organisms.  Several of those approaches have been previously explored for 
FT vaccination, including live attenuated strains, killed bacteria, lipopolysaccharide 
preparations, and purified proteins with various degrees of protection seen in murine 
animal models.  Preliminary results in our laboratory has found that intraperitoneal 
immunization using a FT LVS culture filtrate (CF) preparation offers protection against 
intraperitoneal and intranasal infection in a murine model.  I hypothesized that 
immunization with recombinant forms of FT CF antigens would induce a long-lasting and 
effective immune response against a lethal FT challenge.  The overall goals of the 
studies described herein sought to focus on the following: 1) to identify the protective 
antigens in FT CF and 2) to evaluate the ability of recombinant forms of these antigens 
to stimulate the protective immune responses necessary for developing a safe and 
effective vaccine against tularemia. 
 
 
Introduction 
 
Francisella tularensis (FT) is a highly infectious Gram-negative intracellular 
pathogen which is the causative agent of tularemia.  F. tularensis has been found 
throughout the Northern Hemisphere and infects a variety of vertebrate and invertebrate 
hosts (2, 6). Francisella is the only member of the family Francisellaceae and is 
composed of the two species F. tularensis and F. philomiragia. Of the two Francisella 
species, F. tularensis is made of four subspecies: tularensis (type A), holarctica (type B), 
mediasiatica, and novicida.  The most severe cases of human tularemia are often 
attributed to F. tularensis subsp tularensis (type A) which makes up approximately 2/3 of 
reported cases and found almost exclusively in North American cases of infection (4). 
Human cases of tularemia are often associated with wild game hunters, landscape 
laborers, and laboratory workers (6, 14)  that are exposed to infectious materials such as 
animal tissue (6-7) or by arthropod vectors (6-10).   Because FT is both easily obtainable 
from the environment and highly infectious, this organism is classified as a class A select 
agent by the CDC consequential to its former role as a biowarfare agent (28)  and its 
potential use for bioterrorism purposes.  It is for these reasons that a safe and effective 
vaccine against tularemia is needed.   
 
While our current understanding is that surviving an infection with Francisella 
results in life-long immunity to tularemia in humans, it also opens the possibility that a 
protective vaccine against this disease is possible. Attempts to develop a safe and 
effective vaccine against tularemia have been met with various degrees of success in 
the past.  Some of the first vaccination methods attempted were killed bacterial vaccines 
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tested by Foshay during the 1930’s and 1940’s which consisted of formalin treated, heat 
killed, and oxidized preparations of virulent FT strains, all of which offered very limited 
protection against human tularemia although eliciting significant anti-FT serum antibody 
titers (31).   Protection against infection with F. tularensis is currently limited to 
scarification with an attenuated live vaccine strain (FT LVS) of F. tularensis subsp 
holarctica, but is currently not licensed and does not illicit complete immunity against 
infection with type A strains of FT (26-27, 32).   An attenuated FT Schu S4 strain was 
reported by Twine et al to protect mice against wild-type homologous challenge after 
sublethal infection, though currently untested in humans (33).  Murine models of 
infection have shown that anti-FT antibodies alone are able to protect against infection 
with type B strains of Francisella but in studies using the more virulent type A strains 
interferon, -gamma as well as CD4+ and CD8+ T-cells are needed to survive a lethal 
bacterial challenge (35-36).   Immunization of mice with LPS extracted from FT bacteria 
offers protection against lethal challenge infections with FT LVS, but fails to protect 
against challenge with the highly virulent FT Schu S4 strain (36-37). Furthermore, 
infection of mice using a mutant strain of FT LVS with a transposon-inactivated gene 
encoding wbtA results in an LPS O-antigen-deficient phenotype and further attenuation 
that offers protection in wt FT LVS challenge experiments (38-39) and suggests a 
dispensable role for anti-LPS antibodies in adaptive immune protection against lethal FT 
infection.  Therefore, even though there exists a high level of cross-reactivity between 
antisera of to the LPS O-antigen of both typa A and B subspecies of FT, experimental 
evidence clearly indicates that bacterial antigens other than lipopolysaccharide may also 
play a role. 
   
Various strains of F. tularensis possess homologous features of type II, type IV, 
and the newly described type VI secretion systems found in other bacterial pathogens 
such as Klebsiella, Bartonella, Brucella, Legionella, and Vibrio (132-135) .  Recent 
studies have shown that several immunogenic Francisella proteins are detected in 
culture filtrates from both high and low-pathogenicity strains.  Surprisingly, a single 
report from almost 50 years ago describes a protective immune response against 
virulent Francisella strains following immunization of mice with culture filtrate 
preparations (136).  Preliminary data from our laboratory has shown that immunizing 
mice with culture filtrate (CF) preparations from a wbtA-inactivated strain of FT LVS are 
able to consistently elicit protection in mice from wt FT LVS challenge, which has also 
been used to passively immunize naïve Balb/c mice using pooled sera.  Following up on 
this study, I identified four immunodominant protein antigens (g roL, sucB, aceE, and 
aceF) from Western Blot studies using frozen sera taken from those mice before lethal 
FT LVS challenge.  The work presented here also includes immunization experiments 
using recombinant versions of these and other proteins that are identified.   
 
To date, only a few subunit vaccine formulations have been reported in the 
literature, including recombinant proteins  lpnA (137-138) and fopA (139), despite 
several papers documenting at least 94 FT protein antigens that are recognized by 
immune sera from mice and/or humans (140-143).  The lack of published FT subunit 
vaccine work together with a wealth of available immunoproteomic data clearly indicates 
an opportunity for FT vaccine researchers to explore these antigens in murine 
experiments. 
 
 
 
 
56 
 
Materials and Methods 
 
 
Extraction of FT culture filtrate components 
 
F. tularensis Live Vaccine Strain (FTLVS) was a kind gift of Dr. Karen Elkins 
(FDA, Bethesda, MD).  A 10 μL inoculum taken from frozen stocks of wild-type FT LVS 
or FT LVS 48B10 (LPS O-antigen deficient mutant) were used to start an overnight 
culture in modified Mueller-Hinton (MMH) broth supplemented 0.025% ferric 
pyrophosphate, 0.1% glucose and 0.1% cysteine, 0.625 mM CaCl2, 0.530 MgCl2, (plus 
10 μg/mL kanamycin for FT LVS 48B10 strain) and cultured at 37˚C with 200 RPM 
rotation.  This overnight culture was used to dilute ~500 mLs of pre-warmed MMH to a 
final OD600 reading of 0.1 on a spectrophotometer, using an aliquot of uninoculated MMH 
as a blank.  Frequently, small culture samples were read spectrophotometrically until an 
OD600 reading of 0.4-0.5 was reached.  After reaching this desired mid-log phase culture 
density, the entire culture was dispensed into 2 x 250 mL Cornell conical centrifugation 
bottles, and were spun at 4,000 RPM and 4˚C for 30 minutes.  Carefully, the culture 
supernatant was poured into two additional fresh conical centrifugation bottles and the 
previous step was repeated to pellet any bacteria that became dislodged from the 
bacterial cell pellet.  After the second centrifugation step, the clarified supernatant was 
filtered through a 0.2 micron bottle-top filtration unit to remove any residual bacterial 
cells and particulates.  To this clarified culture filtrate, and equal volume of pyrogallol-red 
molybdate methanol (PRMM) buffer solution (0.05 mM pyrogallol red, 0.16 mM sodium 
molybdate, 1.0 mM sodium oxalate, 50.0 mM succinic acid, 20% [vol/vol] methanol in 
H2O, adjusted to pH 2.0 with HCl) were added into a sterile 1L glass bottle and 
incubated overnight at 4˚C with magnetic stirring to enhance precipitation of the proteins, 
an adaptation of a previously described method.  (144-145)  The PRMM-buffered FT 
culture filtrate was then poured into 4 x 250 mL conical centrifuge bottles, and spun at 
4,000 RPM and 4˚C overnight.  After removing the supernatant, all precipitate material 
was dislodged from the conical bottles using approximately 10 mLs of PBS w/ 2.5% 
glycerol and vigorous pipetting.  The pooled collections of precipitate were then split into 
2 x 30 mL round-bottom polypropylene centrifugation tubes with 100% acetone added to 
a final concentration of 80% (v/v), vortexed, and stored at -20˚C for 30 minutes before 
further centrifugation at 20,000 RPM for 15 minutes at 4˚C.  After the final spin, the 
acetone-containing supernatant is removed and the precipitate is allowed to air-dry at 
room temperature.  To the dry precipitate, approximately 5 mLs of PBS w/ 2.5% glycerol 
was added before vortexing to resuspend the pellet and then frozen at -20˚C for further 
experiments.  Total protein concentrations were spectrophotometrically estimated using 
pyrogallol-red-molybdate buffer and a bovine serum albumin protein standard solution 
and standard curves generated by a shift in absorbance from 470 nm to 590 nm (146). 
 
SDS-PAGE analysis of FT LVS culture filtrate precipitate 
 
Equal amounts of FT LVS whole bacterial lysate and culture filtrate (CF) were 
precipitated using ice cold acetone, incubation at -20˚C for approximately 30 minutes, 
then centrifuged at 15,000 RPM for 20 minutes, removed supernatant, and air-dried at 
room temp.  Each sample was resuspended in 1x Laemmli denaturing SDS-PAGE 
sample buffer with 2-mercaptoethanol, boiled for 15 minutes, and loaded on a 4-20% 
polyacrylamide gradient gel (Pierce) before running ~40 minutes at a constant 150V.  At 
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completion, the gel was Coomassie stained and photographed using a ChemiDocXRS 
system (Bio-Rad Laboratories, Hercules, CA). 
 
 
Murine immunization studies 
 
Groups of 4 female Balb/c mice were immunized intraperitoneally (i.p.) with 50 μg 
of FT LVS CF and/or 0.5 μg rIL-12 (adjuvant), or sterile phosphate-buffered saline (PBS) 
alone in a total volume of 1 mL.  A positive control group was immunized with a sublethal 
inoculum of 5x104 CFU of live FT LVS intradermally (i.d.). Immunizations were given at 
Day 0, 5, and 15.  At +31d after the final immunization, mice were lightly anaesthetized 
with isofluorane and challenged by i.n. infection with 1x104 CFU of live FT LVS in a total 
volume of 50 μL (25 μl/nare).  For passive immunization studies, pooled serum taken 
+25 days after mice were successfully immunized with FT LVS (48B10) CF and rIL-12 
were give to groups of naïve Balb/c mice i.p. (100 μl sera + 400 μl sterile PBS) or 
immune mice (500 µl sterile PBS alone) and challenged 14 hours later with a lethal i.p. 
dose (1x106 CFU) of FT LVS.  Weight and appearance were monitored daily and mice 
losing 20% of their starting weight were sacrificed.   
 
 
Immunoproteomic analysis of sera from FT CF-immunized mice 
 
Immunoprecipitation (IP) experiments were perform using pooled sera (+25d 
after final immunization) from a total of 10 Balb/c mice following immunization with PBS 
or FT LVS CF (48B10) and rIL-12 were mixed with whole bacterial lysate from wild-type 
FT LVS containing a protease inhibitor cocktail.  After incubation at 4˚C for 2 hours with 
rocking, this mixture was added to pre-swollen Protein A Sepharose CL-4B beads (GE) 
to bind antibody-antigen complexes overnight with rocking at 4˚C.  The following day, 
this slurry was gently micro-centrifuged at 1,000 RPM for 2 minutes to remove 
supernatant from the beads, followed by two additional washing steps to remove 
unbound material using PBS and micro-centrifugation at 1,000 RPM.  After pipetting 
away as much of the remaining wash as possible, an equal volume of 2x Laemmli SDS-
PAGE sample buffer containing 2-ME was added to the beads, which were then boiled 
for 10 minutes to completely solublize the Protein A-bound antibody-antigen complexes. 
The samples were removed from the heat and allowed to cool to room temperature 
before briefly micro-centrifuging at 15,000 RPM to pellet the beads.  The supernatant 
was subjected to denaturing SDS-PAGE analysis using 4-20% acrylamide gradient mini-
gels (Pierce) for ~40 minutes at a constant 150V.   After electrophoresis was complete, 
gels were Coomassie stained and stored at 4˚C in gel destaining solution (50% 
methanol + 10% acetic acid).  To confirm IgG specificity from the IP experiments, gels 
containing separated FT proteins were electrophoretically transferred to Immobilon-Psq 
PVDF membranes (Millipore), blocked overnight with 5% non-fat milk in PBS at 4˚C, 
probed with pooled mouse antisera, and detected using a goat anti-mouse IgG-HRP 2˚ 
antibody.  The blots were developed using SuperSignal West Pico Chemiluminescent 
Substrate and images were documented on a ChemiDocXRS system (Bio-Rad 
Laboratories, Hercules, CA). The corresponding immunoreactive bands as seen on 
Western blots were excised from Coomassie-stained gels using sterile scalpels and 
those proteins were identified by mass spectrometry. Four of the most intensely 
immunoreactive FT LVS bands from Western blot analysis were identified using 
vMALDI-LTQ methods similar to those described in Chapter 2.  
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Results 
 
 
Precipitation of FT culture filtrate components using pyrogallol-red molybdate 
methanol buffer 
 
Until recently, little was known about the extracellular proteins and potential 
secretion systems of Francisella (133-134, 147).  Additionally, there have been no 
studies on the immunological response to protein antigens found in the media during 
culture of FT.  I first sought to extract FT culture filtrate (CF) components by utilizing a 
pyrogallol-red molybdate methanol (PRMM) method which has been previously shown to 
enhance the recovery of bacterial proteins (144).  I chose this method because PRMM 
has been shown to allow the precipitation of proteins in solutions that are too dilute to 
extract by other methods, such as those involving cold acetone or trichloroacetate (145).   
To accomplish this, FT LVS was cultured to the intended density in MMH broth, bacteria 
were then removed from the media by centrifugation and sterile filtration, and finally 
combined with PRMM solution and processed as described in the Materials and 
Methods.  Separation of the extracted FT culture filtrate components by SDS-PAGE 
analysis revealed several prominent bands (Fig. C.1).  
 
 
FT LVS culture filtrate as an immunogen against tularemia in a murine model of 
infection 
 
To evaluate the ability of immunizations with FT LVS CF to protect mice from a 
lethal FT LVS intranasal (i.n.) challenge, I injected groups of 4 female Balb/c mice 
intraperitoneally (i.p.) with 50 μg of FT LVS CF and/or 0.5 μg rIL-12 (adjuvant), or sterile 
phosphate-buffered saline (PBS) alone in a total volume of 1 mL.  A positive control 
group was immunized with a sublethal inoculum of 5x104 CFU of live FT LVS 
intradermally (i.d.). Immunizations and subsequent boosters were given at Day 0, 5, and 
15.  At +31d after the final immunization, mice were lightly anaesthetized with 
isofluorane and challenged by i.n. infection with 1x104 CFU of live FT LVS in a total 
volume of 50 μL (25 μL/nostril).  Weight and appearance were monitored daily and mice 
losing 20% of their starting weight were sacrified.  Results from this experiment indicated 
a protective effect in mice receiving FT LVS CF+rIL-12 (100% survival) with an 
increased time to death and survival in the group receiving only FT LVS CF (1/4 
surviving) (Fig. C.2).  As expected, all mice in the PBS group were dead by day 4 and all 
mice receiving a sublethal FT LVS immunization survived through the duration of the 
experiment. Together, these results clearly indicate a protective component in FT LVS 
CF for further evaluation as a potential vaccine against tularemia. Because it is known 
that immunization with (lipopolysaccharide) LPS O-antigen from FT can elicit protective 
immunity against infection with low virulence strains of FT, I wished to determine if this 
component is responsible for the protective effect of FT LVS CF immunization.  To 
evaluate the contribution of LPS O-antigen in the observed protection, a similar 
experiment was conducted using CF derived from an LPS O-antigen deficient mutant 
(FT LVS 48B10).  Surprisingly, a similar protective effect was seen in the LPS O-antigen 
deficient CF as was observed in the experiment using CF from wt FT LVS with all mice 
surviving the study (Fig. C.3).  Additional experiments with Balb/c mice showed that 
protection against infection with FT LVS could be maintained at least 72 days after the  
final immunization, which suggests that the protective effect seen using CF as in 
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Figure C.1.  Coomassie-stained 4-20% SDS-PAGE gel of FT LVS CF precipitate. 
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Figure  C.2. Kaplan-Meier survival plot of Balb/c mice following i.p. immunization 
with FT LVS CF and rIL-12 adjuvant.  Balb/c mice (4/group) were immunized with the 
vaccine formulations indicated on days 0, 5, and 15.  On day 31, all mice were 
challenged i.n. with FT LVS.  The health and survival of the mice were monitored daily 
for signs of tularemia.  Results are reported as days surviving post-challenge with FT. 
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Figure C.3.  Kaplan-Meier survival plot of Balb/c mice following i.p. immunization 
with FT LVS (48B10) CF and rIL-12 adjuvant.  Balb/c mice (5/group) were immunized 
with the vaccine formulations indicated on days 0, 5, and 15.  On day 31, all mice were 
challenged i.p. with FT LVS.  The health and survival of the mice were monitored daily 
for signs of tularemia.  Results are reported as days surviving post-challenge with FT. 
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immunogen is also long-lived (data not shown).  In summary, these data indicate that the  
protective component found in FT LVS CF is not likely LPS, but possibly a protein 
antigen.  
 
 
Sera from mice immunized with FT LVS (48B10) CF can be used to passively 
transfer humoral immunity to naïve mice 
 
  It is thought that protection against FT is mediated by both the humoral 
(immunoglobulins) and cell-mediated (T-cells) adaptive immune responses to these 
bacterial antigens during an active infection.  To determine whether the protection seen 
in the previous experiments were dependant on cell-mediated adaptive immunity, pooled 
antisera taken +25 days after mice were successfully immunized (Fig. C.3) with FT LVS 
(48B10) CF and rIL-12 were give to groups of naïve Balb/c mice i.p. (100 uL sera + 400 
uL sterile PBS) or immune mice (500 uL sterile PBS alone) and challenged 14 hours 
later with a lethal i.p. dose of FT LVS.  As indicated, it was concluded that i.p. injection of 
anti-CF sera could protect mice from lethal FT challenge (Fig. C.4).  Together, these 
data suggest that because immunity from FT LVS CF+rIL-12 –immunized mice could be 
passively transferred to naïve mice, it suggests that FT protein-specific antibodies play a 
role in this model.  These findings also suggest that further investigation on the 
protective effect of FT LVS CF immunization for the possible discovery of novel vaccine 
components against tularemia. 
 
 
Immunoproteomic analysis of passive transfer experiments involving FT LVS 
48B10 CF 
 
To try and elucidate the protective components of the previously successful 
immunization, immunoprecipitation (IP) experiments were performed using pooled sera 
(+25d after final immunization) from a total of 10 Balb/C mice following immunization 
with PBS either FT LVS CF (48B10)+ rIL-12 were mixed with whole bacterial lysate from 
wild-type FT LVS.  This approach allows antibodies from the sera to bind their specific 
antigens for isolation and later identification. After incubation at 4˚C for 2 hours with 
rocking, this mixture was added to pre-swollen Protein A Sepharose CL-4B beads to 
bind antibody-antigen complexes overnight with rocking at 4˚C.  The following day, this 
slurry was gently washed several times with PBS to remove supernatant containing 
unbound FT antigens.  After pipetting away as much of the remaining final wash as 
possible, an equal volume of 2x Laemmli SDS-PAGE sample buffer containing 2-ME 
was added to the beads, which were then boiled for 10 minutes to completely solublize 
the Protein A-bound antibody-antigen complexes. After cooling, the supernatant was 
subjected to denaturing SDS-PAGE analysis using 4-20% acrylamide gradient mini-gels 
(Pierce) to allow separation of the proteins according to their molecular weight.  After 
electrophoresis was complete, gels were then Coomassie stained (Fig. C.5) and stored 
at 4˚C in gel destaining solution (50% methanol + 10% acetic acid). To confirm IgG 
specificity from the IP experiments, duplicate gels containing separated FT proteins were 
electrophoretically transferred to Immobilon-Psq PVDF membranes (Millipore), blocked 
overnight with 5% non-fat milk in PBS at 4˚C, probed with pooled mouse antisera, and 
detected using a goat anti-mouse IgG-HRP 2˚ antibody.  The blots were developed 
using a chemiluminescent substrate and images were documented for analysis (Fig. 
C.6). The corresponding immunoreactive bands as seen on Western blots were excised 
from Coomassie-stained gels using sterile scalpels and those proteins were identified by  
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Figure C.4.  Kaplan-Meier survival plot of naïve Balb/c mice following passive 
immunization with pooled serum from mice immunized with FT LVS CF and rIL-12 
adjuvant.  Balb/c mice (5/group) were passively immunized with the vaccine 
formulations as indicated.  Fourteen hours after receiving injections, all mice were 
challenged i.p. with FT LVS.  The health and survival of the mice were monitored daily 
for signs of tularemia.  Results are reported as days surviving post-challenge with FT. 
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Figure C.5.  SDS-PAGE and Coomassie-stained anti-CFP immunoprecipitated FT 
LVS proteins identified so far using anti-CFP immune sera.  FT LVS protein 
antigens and mouse immunoglobulin chains are indicated. 
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Figure C.6.  Western blot analysis of immunoprecipitated FT LVS lysate using 
pooled negative control sera and anti-CFP sera (1˚Ab) followed by detection with 
goat anti-mouse IgG:HRP (2˚Ab). 
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mass spectrometry. Four of the most intensely immunoreactive FT LVS bands from 
Western blot analysis were identified by using vMALDI-LTQ as GroL, sucB, aceE, and 
aceF.  
  
Unfortunately, later immunization experiments were conducted using 
recombinant forms of the four identified proteins expressed in E coli BL21(DE3) with rIL-
12, but these preparations failed to elicit a protective immune response against FT 
infection. Based on these findings, we therefore concluded that the immunoreactive 
proteins that were identified from FT LVS CF preparations did not warrant further 
immunization experimentation in mice.  Perhaps additional studies utilizing alternative 
methods will allow the protective antigens in FT LVS CF to be isolated and further 
characterized as potential vaccine components against tularemia. 
 
 
Discussion 
 
The effectiveness of F. tularensis as an intracellular pathogen, together with an 
incomplete understanding of the pathogenic mechanisms used by the organism to 
establish infection, have led vaccine researchers to look for unique approaches to elicit 
protective host responses.  However, to date, the only available preventative measure 
against human tularemia is by immunization with the unlicensed FT Live Vaccine Strain 
(LVS), and this protection is thought to be incomplete for type A strains of F. tularensis, 
such as SCHU S4.  The susceptibility of mice to FT LVS and the ability to elicit 
protective immunity following a sublethal infection with this organism have allowed 
researchers in the field an experimental model to tease apart the interaction between FT 
and the host adaptive immune responses outside of BSL-3 conditions.  Recent studies 
have begun to shed light on the extracellular proteins and potential secretion 
mechanisms of various strains of F.  tularensis (133-134, 147) . Our studies have 
indicated that immunization of mice with precipitated FT LVS culture filtrate (CF) 
components can protect Balb/c mice against homologous bacterial challenge.   
 
The LPS O-antigen is known to elicit a protective immune response against FT 
LVS in murine models.  Because it is likely that co-precipitation of FT LPS along with 
proteins in our CF preparations by the PRMM buffer might have been a major immune 
determinate in our murine immunization models, an additional CF preparation was made 
using an LPS O-antigen deficient mutant of FT LVS. Additional studies found that CF 
prepared using an LPS O-antigen deficient strain of FT LVS (48B10) could also elicit 
protective immunity, thus ruling out a requirement for antibodies specific for LPS O-
antigen in this model.   
 
To further define the role of adaptive humoral immunity afforded by FT LVS 
48B10 CF, passive transfer experiments were performed using pooled sera from 
immunized mice which transferred serum-mediated protection against wild-type FT LVS 
lethal challenge to naïve mice.  Since there was protection afforded by the passive 
transfer of FT CF from bacteria lacking the complete O-antigen, this suggested to us that 
protein antigens within this prep were responsible for the successful immunization 
against FT LVS.  Using pooled anti-CF sera from successfully immunized mice, I 
performed immunoprecipitation experiments, followed by the SDS-PAGE molecular 
weight separation and mass spectrometric identification of four highly immunoreactive 
protein antigens (aceE, aceF, sucB, and GroL) excised from polyacrylamide gels.   
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However, an experiment in which recombinant forms of these proteins were expressed 
and purified from E. coli failed to elicit protection against challenge with FT LVS.   
 
It is not clear why immunization with recombinant FT CF proteins failed to protect 
the mice in our challenge experiment, despite the presence of antibodies to the given 
antigens.  One possible explanation might be a difference in the way that these proteins 
are post-translationally modified in E. coli versus FT LVS which caused them to be less 
effective than naturally derived antigens from FT CF.  Another critical issue with the CF 
immunization model was that there was a lack of protection seen in mice when 
challenged with the highly virulent FT SchuS4.  Together, these data made it impractical 
to carry out additional experiments with any likelihood of positive results and the CF 
project was suspended indefinitely.   
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